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Zusammenfassung Deutsch  
Einleitung 
Die ileofemorale arterielle Gefäßprotheseninfektion ist eine seltene Komplikation, die eine 
hohe Morbidität und Mortalität verursacht. Das führt meistens dazu, dass sich die klinischen 
Ergebnisse verschlechtern, die Lebensqualität leidet und die Krankenhauskosten steigen. 
Die Risikofaktoren, die zu einer Gefäßinfektion im Ileofemoral-Bereich führen, können sehr 
unterschiedlich sein und durch vielerlei Faktoren bedingt sein. Die Modifikation von 
Risikofaktoren kann das klinische Ergebnis verbessern und kann ökonomisch sinnvoll sein . 
Die Behandlung von Gefäßprotheseninfekten stellt auch heutzutage eine sehr große 
Herausforderung im Bereich der Gefäßchirurgie dar. Das Infektionsmanagement schließt 
mehrere  Behandlungsmethoden ein. Dazu zählen u.a. die chirurgische Behandlung mit 
Sanierung der Infektion (Goldstandard), und im Anschluss die Vacuum Assisted Closure 
Therapie (VAC) oder eine kontinuierliche  Saug-Spül Drainage (SSD)  in Kombination mit 
einer  Breitspektrum Antibiotika-Therapie. 
Die VAC Behandlung spielt eine zunehmende  Rolle in der Behandlung der 
Gefäßprotheseninfektion. Vor allem im letzten Jahrzehnt wurden gute klinische Ergebnisse für 
diese Therapie publiziert. Eine andere Methode ist die SSD Therapie für die Behandlung der 
Gefäßprotheseninfektion. Diese Therapiemethode ist im Vergleich zur VAC Therapie etwas 
wenig modern, jedoch wurden auch in der Vergangenheit gute Ergebnisse berichtet. 
Hypothese 
Diese Untersuchung  besteht aus zwei Teilen: Teil 1 analysiert die verschiedenen 
Risikofaktoren, die einen Einfluss auf die Entwicklung der Gefäßprotheseninfektion nach der 
Operation haben können. In dieser Studie werden nicht nur traditionelle Risikofaktoren 
analysiert, sondern auch einigen spezifische Risikofaktoren wie Elektrolytstörungen, frühere 
orthopädische und unfallchirurgische Eingriffe im Bereich der Gefäßprotheseninfektion sowie 
die Auswirkungen von Chemotherapie und Bestrahlungstherapie. Die Auswirkungen dieser 
Risikofaktoren sind in bisherigen publizierten Veröffentlichungen nicht ausreichend 
dokumentiert. 
 
 
Der zweite Teil dieser Studie umfasst die Analyse zweier  Behandlungsmethoden bei 
Gefäßprotheseninfektion: Die VAC Therapie und SSD Therapie. Analysiert werden die 
klinischen Ergebnisse und wirtschaftliche Aspekte dieser beiden Behandlungsmethoden. 
Material und Methoden 
Insgesamt 57 Patienten mit Gefäßprotheseninfektionen im Ileofemoral-Bereich im Zeitraum 
zwischen 2007 und 2015 wurden in diese Studie miteinbezogen. Das Contilia Herz und 
Gefäßzentrum Essen führte insgesamt 6323 Operationen bei peripherer arterieller 
Verschlusskrankheit im Ileofemoral-Bereich in diesem Zeitraum durch. 
Die Patienten stimmten bei Aufnahme der systematischen Erfassung von Daten zur 
Qualitätssicherung zu. 
Die Patienten wurden retrospektiv  in zwei Gruppen aufgeteilt: In die  erste Gruppe wurden 
Patienten mit einer Gefäßprothesen-Infektion, die mit der VAC Therapie behandelt wurden, 
aufgenommen. Die zweite Gruppe schloss  Patienten ein, die mit SSD Therapie therapiert 
wurden. 
Die Akten der konsekutiven Patienten wurden retrospektiv analysiert, um mögliche 
Risikofaktoren und Ausschlusskriterien zu identifizieren. Zusätzlich wurden  
Entzündungsparameter, Transfusionsparameter, Aufenthaltsdauer auf  der Intensivstation, 
Gesamtaufenthalt sowie Morbidität und Mortalität retrospektiv erfasst.  
Bakteriologische Kulturen von tiefen Wundabstrichen sowie Antibiotika-Therapien  wurden 
ebenfalls für jede Patientengruppe analysiert. Die Schwere der Gefäßprotheseninfektion bei 
allen beobachteten Patienten wurde  nach Szilagyi klassifiziert.  
Die follow-up Zeit nach der ersten gefäßchirurgischen Revision in dieser Studie betrug ein Jahr. 
Sobald die Patienten eine erneute  Gefäßprotheseninfektion im Zeitraum dieses einen Jahres 
entwickelten, wurde eine detaillierte Analyse der Patientendaten für ein halbes Jahr nach der 
ersten Diagnose einer Gefäßprotheseninfektion durchgeführt. 
Der ökonomische Aspekt wurde für beide Gruppen nach der ausgewählten Therapieoption 
abgewägt: VAC Therapie oder SSD Therapie. Die Materialkosten  für jede Therapiemethode 
wurden sowohl pro Tag als auch als gesamte Behandlung für beide Gruppen berechnet. 
 
 
 
Ergebnisse 
In die Studie wurden insgesamt 57 Patienten eingeschlossen, 21 Patienten in die SSD Therapie 
Gruppe, 36 in die VAC Therapie Gruppe. Der Altersdurchschnitt lag bei 66,8 Jahren (von 34 
bis 82) in der SSD Gruppe und 71,3 Jahren (von 55 bis 90) in der VAC Gruppe. In der SSD 
Gruppe waren 33,3% weibliche und 66,7% männliche Patienten, während in der VAC Gruppe 
36,1% weiblich und 63,9% männlich waren. Die durchschnittliche Aufenthaltsdauer im 
Krankenhaus betrug 34 Tage für die SSD Gruppe und 38 Tage für die VAC Gruppe. Der 
Aufenthalt auf der  Intensivstation betrug 5 Tage in der SSD Gruppe versus 4 Tage in der VAC 
Gruppe. 
Die am häufigsten isolierten bakteriologischen Spezies aus dem Infektionsareal  waren in 
beiden Gruppen Staphylococcus aureus sowie Methicillin-resistenter Staphylococcus aureus. 
Andere häufig auftretende Mikroorganismen enthalten Escherichia coli und Pseudomonas 
aeruginosa. Es gab keine Unterschiede in den isolierten Mikroorganismen zwischen beiden 
Gruppen. 
Die Analyse der  Risikofaktoren wie Diabetes, Elektrolytstörungen, Nikotinabusus oder 
Alkoholmissbrauch usw. zeigte keinen statistisch relevanten Unterschied zwischen den beiden 
Gruppen. Jedoch waren diese Faktoren bei vielen Patienten in beiden Gruppen vorhanden und 
spielten eine wichtige Rolle bei  der Entwicklung der vaskulären  Implantatinfektion. 
Die Amputationsraten betrugen in der SSD Gruppe 33,3% (7/21) und in der VAC Gruppe 27,8% 
(10/36), die Mortalitätsraten 9,5% (2/21) und 8,3% (3/36) für die SSD Gruppe und die VAC 
Gruppe. Beide Parameter zeigten keine statistisch signifikanten Unterschiede zwischen den 
Gruppen (p> 0,05). 
Die Initialkosten der SSD Therapie betrugen 20,50 €. Die Materialkosten pro Tag waren 4,36 
€. In der VAC Gruppe kosteten die Behandlungen - je nach Wundbereich - von 276,08 € bis 
293,44 €. Die Materialkosten für VAC Wechsel - die alle 4 Tage durchgeführt wurden - reichten 
von 73,32 € bis 84,60 €, je nach Wundbereich. Dies führte zu einem statistisch-signifikanten 
Unterschied (p <0,01) zwischen den beide Gruppen. 
 
 
 
 
 
Zusammenfassung 
Gefäßprotheseninfektionen im Ileofemoral-Bereich sind  schwere Komplikationen mit 
erheblichen klinischen und wirtschaftlichen Konsequenzen  und beeinflussen die 
Lebensqualität der Patienten immens. 
 Die Risikofaktoren für eine Gefäßprotheseninfektion sind  Diabetes mellitus, Nikotinabusus 
oder Alkoholmissbrauch und Arteriosklerose. Diese Risikofaktoren wurden nicht nur in beiden 
Patientengruppen sondern auch in der publizierten Literatur ausreichend dokumentiert. Durch 
die Studie wurden auch Elektrolytstörungen oder frühere chirurgische Operationen bzw. 
Manipulationen im Ileofemoral-Bereich als Risikofaktor charakterisiert und könnten kausal bei 
der Entwicklung der Gefäßprotheseninfektion sein. Weitere Studien sollten zukünftig folgen, 
um diese Risikofaktoren weiter detailliert zu analysieren. 
Die VAC Therapie oder die SSD Therapie sind zu Therapie der ileofemorale 
Gefäßprotheseninfektion geeignet.  
Obwohl beide Methoden in dieser Studie ähnliche klinische Ergebnisse zeigte,  schien die SSD 
Therapie einen ökonomischen Vorteil im Vergleich zur VAC Therapie zu besitzen. Nachteil 
der SSD Therapie ist, dass diese nur angewandt werden kann, wenn der Patient  kleinere 
Wundflächen hat. Patienten mit ausgeprägt infizierten Wundbereichen (> 80 cm2) sollten nur 
mit der VAC Therapie behandelt werden. 
  
 
 
Abstract 
Introduction 
Lower extremity vascular graft infection is a rare but potentially hazardous complication 
associated with long hospital stay, worsened clinical outcome, poor quality of life, and high 
hospital costs.  
The risk factors leading to vascular graft infection are very specific and are mostly 
multifactorial. Reduction of risk factors can improve vascular graft surgery outcome and has 
an important impact on economics.  
Vascular graft infection is one of the most challenging issues in vascular surgery. Graft 
infection management includes different treatment methods, such as graft surgery (gold 
standard), vacuum assisted closure therapy (VAC), and irrigation suction drainage (ISD), in 
combination with antibiotic therapy.  
VAC therapy is playing an important role in vascular graft infection management, especially 
in the last 2 decades, with good results.  ISD therapy is for vascular graft infection management 
alternative method; this elder technique, however, shows good clinical outcomes, as well. 
Objectives 
This study was divided into 2 parts – part 1 involved the analysis of different risk factors that 
may have an effect on the development of vascular graft infection after surgery. In this study, 
not only traditional risk factors but also several specific factors, such as electrolyte imbalance, 
previous orthopedic procedures on the ipsilateral site of the vascular graft, and the impact of 
chemotherapy and radiation therapy have been analyzed. The impact of some of these risk 
factors is not well documented in articles that have already been published. 
The second part of this study involved analysis of 2 vascular graft infection management 
methods – vacuum assisted closure therapy and irrigation suction drainage therapy. The clinical 
outcomes of patients subjected to the 2 methods have been analyzed, as well as economical 
aspects. 
Materials and Methods 
57 patients with lower extremity vascular graft infections in the time period between 2007 and 
2015 were included in the study. The Contilia Heart and Vascular surgery center performed 
 
 
6323 lower extremity arterial graft operations overall during the respective time period. 
Patients were divided into 2 groups based on clinical management: in the first group, vacuum 
assisted drainage (VAC) therapy was used to manage vascular graft infections, while in the 
second group, irrigation suction drainage (ISD) therapy was used. The patients’ clinical 
histories were analyzed retrospectively to identify possible risk factors for the development of 
vascular graft infection. Additionally, inflammatory parameters, transfusion parameters, length 
of stay in the intensive care unit (ICU), and total length of stay during the time of vascular graft 
infection management, as well as morbidity and mortality were analyzed. Bacteriological 
probes of wound swabs, as well as antibiotic therapies, were analyzed for each patient group 
retrospectively. Graft infections in all of these patients were classified according to Szilagyi's 
classification. The follow-up period after initial vascular graft surgery in this study was 1 year. 
If patients developed vascular graft infection, follow-up period after diagnosed infection was 
6 months. 
The economical aspect was analyzed for both groups according to the selected therapy option: 
ISD therapy or VAC therapy. The technical equipment costs for each therapy method were 
calculated and compared per day, as well as the total treatment costs for both groups. 
Results 
A total of 57 patients were included in this study. Of these, 21 patients were included in the 
ISD group, while 36 patients were included in the VAC group. Median age was 66.8 years 
(range, 34-82) in the ISD group vs. 71.3 (range, 55-90) in the VAC group. In the ISD group, 
33.3% were female and 66.7% were male, while in the VAC group, 36.1% were female and 
63.9% were male. Mean length of stay in the hospital was 34 days for the ISD group vs. 38 
days for the VAC group. Mean duration of ICU stay was 5 days in the ISD group vs. 4 days in 
the VAC group. 
The most commonly isolated bacteriological species from the surgical site infections were 
Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus. Other common 
microorganisms included Escherichia coli and Pseudomonas aeruginosa. There were no 
differences in the isolated microorganisms between the groups (table 5).  
Analysis of lower extremity risk factors showed no statistical difference between the groups 
with regard to vascular graft infection risk factors such as diabetes, electrolyte imbalance, 
smoking, alcohol abuse, etc. However, these factors were present in many patients in both 
 
 
groups and are likely to play important roles in vascular graft infection development (table 12, 
13, 23).   
With regard to clinical outcomes, we reviewed the amputation rates and mortality rates of the 
patients in both groups. Amputation rates were 33.3% (7/21) and 27.8% (10/36), while 
mortality rates were 9.5% (2/21) and 8.3% (3/36) for the ISD group and the VAC group, 
respectively. Both parameters showed no statistically significant differences between groups 
(p>0.05).   
The initial cost of the ISD therapy was 20.50 € and the technical material costs per day was 
4.36 €. For the VAC group, depending on the wound area, the initial treatment costs ranged 
from 276.08 € to 293.44 €. The costs of changing of VAC materials, which was performed 
every 4 days, ranged from 73.32 € to 84.60 €, depending on the infected wound area. This 
caused a significant difference (p<0.01) in costs between the 2 groups.  
Conclusions 
Lower extremity graft infection is a serious complication of vascular graft surgery with 
significant economic implications and affects the patient’s quality of life.  
Majority of factors that increase the risk of developing vascular graft infection, such as diabetes 
mellitus, nicotine or alcohol abuse, and atherosclerosis, are present in our study patients, and 
have already been well-documented. The presence of electrolyte imbalance and previous 
orthopedic procedures in the vascular graft operative region were likewise noted in our study, 
and could have a role in the development of infection. Future studies, however, need to be done 
in order to prove this. 
The management of vascular graft infection involved different options, such as VAC therapy 
or ISD therapy.  
Although both methods showed similar clinical outcomes, ISD therapy appeared to be more 
advantageous than VAC therapy when analyzed in terms of economic. However, ISD therapy 
had some restrictions for use, depending on the infected wound area; specifically, it cannot be 
performed in large infected wound areas (>80 cm2). 
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Abbreviations 
 
BMI  Body Mass Index 
CRP C-Reactive Protein 
DHS Dynamic Hip Screw 
DRG  Diagnosis-Related Group System  
GSV  Great Saphenous Vein 
ICD-10   10th revision of the International Statistical Classification of Diseases and          
Related Health Problems 
ICU  Intensive Care Unit 
ISD  Irrigation Suction Drainage 
MRSA  Methicillin-resistant Staphylococcus aureus  
NaCl  Natrium Chloride 
RBC  Red Blood Cell 
PAD   Peripheral Vascular Disease 
PTFE  Polytetrafluoroethylene Prosthesis 
PU Polyurethane Ether  
VAC  Vacuum Assisted Closure Therapy 
VRSA Vancomycin-resistant Staphylococcus aureus 
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Introduction 
Peripheral vascular graft infections are rare complications related to vascular graft surgery; 
complication rates vary from 1 up to 6 percent (70). Most vascular graft infections develop in 
patients with prosthetic graft implantation and seldom affect autologous vein grafts.  
There is also a difference in vascular graft infection epidemiology, in terms of vascular graft 
localization. For example, aortic graft infection rates are lower, but at the same time, 
development of aortic prosthesis infection has more dramatic consequences compared to 
peripheral arterial graft infections. Peripheral vascular graft infections are uncommon and 
mostly develop in the ileofemoral region. 
Another important issue in vascular graft infection risk factors represents the fact that prosthetic 
graft infection is more common after emergency procedures for ruptured aneurysms, and when 
prosthetic grafts have been implanted in the femoral region. The incidence of prosthetic graft 
infection following emergent surgical thoracic aortic procedures is significantly lower than 
after abdominal procedures or peripheral vascular interventions (95). 
Another serious problem that makes studies about peripheral vascular graft infection difficult 
is that infection can develop a long time after vascular graft surgery, sometimes years after 
surgery. 
Obviously, bacterial contamination is the main factor in the development of vascular graft 
infection. Bacterial contamination of the implant material and incorrect sterilization of 
operation instruments are rare but are important graft infection factors. Bacterial contamination 
may also occur via other routes, such as the hematogenous route or bacterial migration from 
subcutaneous tissue or skin flora. Lymphatic spread of infection is another particular route, 
mostly known to be associated with lower extremity vascular graft infection development; 
however, this remains to stay under discussion (31). 
Infection at the beginning can be latent and usually does not have any symptoms; however, 
with time, it results in weakening of the vessel wall and disruption of the anastomosis. The 
inflammatory process results in the precipitation of aneurysmal dilatation, hemorrhage, and 
fistula formation. Vascular graft infection cannot only be associated with prosthesis erosion 
and life-threatening bleeding complications, but can also lead to serious septic complications 
with high mortality.  
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Until now there have not been many publications about this topic, there is still little available 
information with respect to optimal surgical and antimicrobial therapy approaches in the 
management of lower extremity vascular graft infection. In fact, most recommendations for 
treating lower extremity vascular graft infection are based mainly on small case series and 
expert opinion (28). 
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Classification of Vascular Graft Infections  
Vascular graft infection is a general term. Conditions that fall under vascular infection include 
not only prosthesis infection, but also infection of tissues or skin in the area of the vascular 
graft. Vascular graft infection classification plays an important role in classifying the severity 
of peripheral vascular graft infection and is an important factor in developing specific 
management methods for infection according to the location of infection. Nowadays, the 
vascular community continues to use classification methods created 60 to 70 years ago. The 
two most common classifications are the Szilagyi classification (96) which is used in the 
analysis of this study, and the Samson classification (80). Not so well known is another 
classification method known as the Karl-Storck classification (Table A). 
Table A 
Groups Szilagyi Samson Karl-Storck 
I 
infection involves only the 
dermis 
infections extend no deeper 
than the dermis 
superficial infection without 
involvement of the graft 
II 
infection extends into the 
subcutaneous tissue but does 
not invade the arterial implant 
infections involve 
subcutaneous tissues but do 
not come into grossly 
observable direct contact with 
the graft 
partial graft infection without 
involvement of the 
anastomosis 
III 
the arterial implant proper is 
involved in the infection 
infections involve the body of 
the graft but not at an 
anastomosis 
involvement of the 
anastomosis and suture line 
IV  
infections surround an 
exposed anastomosis but 
bacteraemia or anastomotic 
bleeding has not occurred 
wound disruption and 
complete exposure of the 
graft/patch 
V  
infections involve a graft to 
artery anastomosis and are 
associated with septicaemia 
and/or bleeding at the time of 
presentation 
all the above groups with 
concomitant septic 
bleeding/pseudoaneurysm 
VI   
all the above groups with 
graft thrombosis or septic 
emboli 
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Risk factors of Peripheral Vascular Graft Infections  
Nicotine abuse 
Nicotine abuse is a well-known risk factor of many diseases, such as cardiovascular diseases 
and oncological diseases. Patients with a history of nicotine abuse have a significantly increased 
risk of atherosclerosis, which results in peripheral arterial disease (PAD) or thromboangitis 
obliterans. There are many publications that report nicotine as one of the risk factors of (PAD) 
(108, 98). Nicotine affects the arterial wall directly. However indirect mechanisms increase in 
PAD development as well. Publications mostly show the negative effect of nicotine on the 
vascular graft after lower extremity vascular reconstructive surgery. Patients with a history of 
nicotine abuse undergoing peripheral vascular surgery  suffer from a high number of 
postoperative complications, such as wound healing problems, postoperative lung infections, 
and lower extremity vascular graft infection. According to a study by Willigendale et al., it is 
important to clarify the status of tobacco use preoperatively because nicotine abuse puts the 
patients at higher risk for vascular complications, and the risk correlates with the daily amount 
of tobacco use preoperatively. In this study, they noted a 3 times greater risk of vascular graft 
failure in smokers compared to non-smokers undergoing vascular graft surgery (107). It is 
important to perform nicotine restriction if time allows, in order reducing these risks (98).  
Cardiovascular disease 
Cardiovascular disease is one of the risk factors related to PAD, as well as to graft infection. 
Usually, valvular heart disease and coronary artery disease are associated with factors that 
cause peripheral arterial damage. High blood pressure damages coronary arteries and peripheral 
blood vessels, increasing PAD risk. According to current studies, approximately 35-55% of all 
patients with PAD have hypertension (25). Some studies report that patients with end-stage 
PAD tended to have hypertension that is either not diagnosed or poorly managed. 
Cardiovascular risk factors are predictive of the development of PAD requiring surgical 
intervention. This means that cardiovascular disease is an indirect risk factor for vascular graft 
infection, as it basically increases PAD risk (86). 
Atherosclerosis 
Atherosclerosis has a tremendous effect on the arterial wall. The effect of atherosclerosis 
includes thrombosis, endothelial dysfunction, lipid disturbances, platelet activation, 
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inflammation, oxidative stress in the arterial wall, vascular smooth cell activation, altered 
matrix metabolism and remodeling. All these factors are related to PAD development (27). 
Similar to cardiovascular disease, atherosclerosis is an indirect risk factor for vascular graft 
infection. There are reports that through time, atherosclerosis can have a negative impact on 
implanted vascular grafts by damaging them (105).  
Another important effect of atherosclerosis was reported by Goran K et al. In  his study,  he 
reported that atherosclerosis reduce immune response. These changes can increase risk of  
decreased immune response in patients with PAD who undergo vascular graft surgery and 
increase risk of early vascular graft infection (41).  
Cerebrovascular disease 
Cerebrovascular disease and cardiovascular disease have more or less analogous mechanisms. 
Usually, cerebral stroke is caused by the same factors that cause peripheral or coronary artery 
damage. This parameter was analyzed as a risk factor for vascular graft infection in our study, 
as well as in many already published studies. It is considered as an etiological factor connected 
with cerebral blood vessel damage. The damage in cerebral blood vessels correlates with  
peripheral arterial damage, and it has been reported that changes in the cerebrovascular system 
can cause vascular graft damage, as well (21).      
Diabetes mellitus 
Diabetes (insulin and non-insulin dependent) is an important risk factor for PAD development. 
The gold standard nowadays is detection of glycosylated hemoglobin in diabetes patients. 
Selvin et al. have reported that increase in insulin dependent diabetes mellitus is related to 
increases the risk of PAD by about 25% (84). Over time, most diabetic patients develop 
neuropathy and microangiopathy, which is associated with arterial damage and PAD 
development. 
Diabetes is associated with a decreased immunological response to infection that relates to the 
elevated vascular graft infection risk. Aside from a higher risk of vascular graft infection, there 
have also been reports that patients with diabetes mellitus have higher extremity amputation 
rates when compared with PAD patients without diabetes in the medical history.  Mortality 
rates showed similar trends, indicating a 3 times higher mortality in patients with diabetes 
mellitus undergoing ileofemoral reconsturctions. (51).  
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There are some specific characteristics of arterial damage in diabetes patients. The PAD more 
frequently involves arteries anatomically distal to the knee when we compare with patients 
without diabetes mellitus (51, 40). 
Diabetes is a well-known cause of surgical site infection as it is related with surgical wound 
healing problem and surgical site inflammation. There are studies which have analyzed tight 
glucose control preoperatively and perioperative, as well as postoperatively, in diabetic 
patients, in order to determine if glycemic control can reduce cardiovascular complications and 
surgical site complications, such as healing problems and infection development. However, 
these studies failed to show a decrease in surgical site wound complications, most likely owing 
to the deleterious effects of diabetes aside from hyperglycemia (93, 85). 
Alcohol consumption 
Alcohol has been extensively discussed as a risk factor for PAD and vascular graft infection. 
Most authors who have published studies about the impact of alcohol on the vascular system 
say that alcohol can have both positive and negative effects on the arterial wall. There are some 
studies, which report that alcohol in small doses reduces the risk of PAD, but moderate alcohol 
doses increase the PAD risk (103). Giles et al. reported that alcohol use in moderate doses is 
an important risk factor for PAD development (20).  
As already mentioned, alcohol consumption has negative effects on the development of 
vascular graft prosthesis infection, serving as both a direct and indirect risk factor. Romeo et 
al. in his review article showed that the effect of high doses of alcohol consumption could 
directly suppress a wide range of immune responses and these results in an increased incidence 
of infection, which develops after peripheral vascular graft implantation. The consequences of 
alcohol abuse result in decreased immune response to the microorganisms that can colonize 
vascular grafts (79). 
Obesity 
Obesity is huge problem nowadays, and the trend has a tendency to rise, especially in high 
income countries. Obesity is a well-described risk factor for PAD development, and is likewise 
a direct risk factor for vascular graft infection.  
Usually, obesity is associated with comorbidities, such as hypertension, dyslipidemia, and 
diabetes mellitus, which are themselves risk factors for PAD development and vascular graft 
infection (36). In addition, obesity is a predictive factor for surgical site infection in general 
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surgery and cardiac surgery, but there are also data about lower extremity vascular graft 
infection. Some studies found that obesity increases the risk of vascular graft infection, while 
other studies showed no statistically significant difference in the effect of obesity on vascular 
graft infection (36, 47, 67). Obesity has a positive effect on mortality rate after peripheral 
vascular graft infection.  Thus, patients with normal or reduced body mass index (BMI) showed 
higher mortality compared to patients who are overweight (36). Kannel et al. found a 
correlation between elevated BMI and vascular graft infection. In this study, patients with 
increased BMI had slower progression of vascular graft infection (54). Other large 
epidemiological studies reveal the same results: that elevated BMI reduces vascular graft 
infection mortality and reduces PAD development as well as PAD progression (68, 26).  
One of the negative effects of obesity is that patients who undergo vascular graft operations 
due to PAD have a higher incidence of wound hematoma, wound necrosis or seroma 
development. If these complications occurs patient requires revision operations, and the risk of 
vascular graft infection becomes higher (75).   
Other risk factors 
Other risk factors include those that can play a direct or indirect role on vascular graft infection 
development. These factors are not so commonly analyzed in previous studies. Such factors 
include kidney insufficiency and dialysis, electrolyte imbalance, foreign materials in the 
vascular graft implantation area, liver insufficiency, malnutrition, and lung diseases such as 
asthma and chronic obstructive bronchitis. Some of these factors definitely play a role as 
indirect factor for vascular graft infection, such as chronic obstructive bronchitis, which usually 
is a consequence of nicotine abuse. On the other hand, lung diseases such as asthma could 
increase the risk of vascular graft infection because of immunological mechanisms that lead to 
decreased immunity (97). Electrolyte imbalance is documented as a possible risk factor; 
however, only 1 study analyzes electrolyte changes and their correlation with vascular graft 
infection (38). 
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Vascular Graft Infection Pathophysiology 
Vascular graft infection usually develops after bacterial contamination of the vascular graft. 
The vascular graft can be infected by some rare bacteria, such as mycobacterium, mycoplasma, 
or a fungal species (31, 27, 37)  
Most contamination happens in the operation due to the patient’s skin flora. There are several 
publications saying that soft tissue edema or injured skin structures in the operative area 
increase the risk of vascular graft infection development (83). Other possible infection routes, 
which are very rarely seen nowadays, include incompletely sterilized surgical instruments or 
vascular grafts. It has been reported that in emergency cases or in emergency reoperations, such 
as in cases of acute bleeding, the risk for an incompletely sterilized operative field will be higher 
and the risk for the occurrence of postoperative surgical site infection will also be greater (101). 
Yeager et al published another risk factor for possible postoperative infection. He reported that 
the risk for bacterial contamination increases with operation time and blood loss during the 
operation (109).   
The infection can spread via the hematogenous route, whereby bacteria spread from other acute 
or chronic bacterial infections in the patient’s body, such as urinary tract infections, or through 
dental procedures, or urological or endoscopic manipulations in the postoperative period. 
Usually, the hematogenous route is associated with late vascular graft infections.  
The vascular graft implant develops infection through biofilm formation. A wide spectrum of 
microorganisms have been reported that can cause graft infections; however, the most common 
species isolated are Staphylococcus aureus and Streptococcus epidermidis (61).   
Nowadays, many patients who undergo vascular graft implantation have significant amounts 
of mucin-producing coagulase-negative staphylococci on their skin, and at least 15% have 
methicillin-resistant (MRSA) strains preoperatively. This causes increasing vascular graft 
infection cases in which the MRSA strain has been isolated (55).  
Pathogenically, mechanisms include bacterial invasion of the vascular graft or in perigraft 
tissues during the operation or in the early postoperative period. In the early postoperative 
period, the fluid-filled perigraft tissue environment is poorly perfused with blood and lymph, 
and for this reason, is isolated from the natural host defenses (23). In addition, the poorly 
vascularized perigraft area provides a good condition for bacteria to survive and proliferate. 
For this reason, even a very small amount of bacterial species can lead to possible prosthetic 
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graft infection. With time, the vascular graft material adapts to the patient’s tissues; when the 
operated tissues have been better vascularized, the risk of development of prosthetic infection 
decreases.      
Vascular Graft Infection Microbiology 
There is a wide spectrum of pathogenic bacterial species, which are linked to vascular graft 
infection. The most common species include Staphylococcus aureus; however, the trend in the 
last decade is a decrease in vascular graft infection due to Staphylococcus aureus species due 
to perioperative antibiotic therapy. Nowadays, there are trends of increasing vascular graft 
infections due to normal skin flora and multi-resistant bacteriological strains (5).  
On the other end of the spectrum is the situation with methicillin-resistant Staphylococcus 
aureus (MRSA). In the last decade, there have been many more reports about MRSA-induced 
vascular graft infection (8). Due to plasmid-mediated mutation of Staphylococcus aureus, the 
bacteria become resistant against beta-lactam antibiotics, as well as other antibiotic groups. As 
already mentioned, MRSA infection rates causing vascular graft infection have been 
increasing. The explanation could be that MRSA has now been often found in skin flora by 
population screening. PAD, in its end stage, when it requires ileofemoral graft implantation, 
leads to decreased immunity, which is very favorable for the MRSA species to cause graft 
infection. Another important point is that patients with end-stage PAD often have multiple 
diseases, which require prolonged hospital stay, resulting in a higher possibility to acquire 
MRSA infection (42). Kaebnick et al. have reported that in bacteriological analyses, more than 
half of early extracavitary vascular graft infections have shown that the most common 
microorganism was MRSA. Data is lacking with regard to the effect of MRSA infection on 
early mortality, infection recurrence or amputation rates, as compared to other bacteriological 
species (52).  
Moreover, there are alarming trends that vancomycin-resistant Staphylococcus aureus (VRSA) 
will become the most common isolated pathogen in vascular graft infections based on 
bacteriological analysis in the next decade. The first VRSA has been isolated in 2002 from a 
dialysis shunt in a patient with multiple comorbidities, namely diabetes, foot ulcer, kidney 
dysfunction, and PAD. After this, VRSA has been isolated more and more often from infected 
vascular graft prostheses (92).     
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An interesting trend shows specific bacteriological species over time. In other words, there are 
differences in microorganisms that are isolated in an early vascular graft infection and in a late 
vascular graft infection. Early vascular graft infection is mostly caused by coagulase-positive 
Staphylococcus aureus, Escherichia coli, Proteus species, and Pseudomonas aeruginosa. 
Meanwhile, late infection, which develops after a few months or later, is mostly caused by 
Staphylococcus epidermidis or very rare fungal species (14, 33).  
There are some studies, which have isolated specific microorganisms in cases of vascular graft 
infection, but in general, such cases are exclusions. For example, anaerobic bacterial species 
have been isolated from femoral graft infections. Usually, this affects patients with decreased 
immunological system response, such as patients with diabetes, leg ulcer, gangrene, or patients 
with a history of chemotherapy or radiation therapy (12). The previously mentioned fungal 
vascular graft infections show the same trend, and mostly affect patients with immunological 
deficits.   
In many cases, the microbiological culture from the infected graft reveals two or more different 
microbiological species. Calliagro et al. in their study analyzed 42 patients with graft infections, 
and have seen that in 16 cases, both gram-positive and gram-negative species have been found 
(19).  
Vascular Graft Infection Management 
Vascular graft infection management is a challenge for all medical staff  who take part in patient 
treatment. Infection management usually includes management of infected vascular graft 
hemorrhage, preservation of lower limb blood circulation, control of infection parameters, and 
sepsis prevention or early excessive treatment if septic symptoms develop.  One of the most 
important ileofemoral vascular infection management methods includes lower limb 
revascularization via extra-anatomic pathways and excision and debridement of infected tissues 
(81, 35). Nowadays, there are tendencies to reduce aggressive surgical approaches, and instead 
proceed with more lenient surgical management and put more accent to proper antibacterial 
therapy, as well as to nutritional support. Other tendencies include methods such as rinse 
suction drainage or vacuum assisted drainage, which plays a more important role in vascular 
graft infection management (3, 10).  
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Surgical management of vascular graft infection 
Surgery is one of mainstays in lower extremity vascular graft management. The important point 
in surgical management is the time when vascular graft infection is diagnosed.  
Due to radiological diagnostic problems, there are still infections that are diagnosed late with 
septic symptoms, hemorrhage or hypovolemic shock. A combination of blood products and 
intravenous volume resuscitation, wide spectrum antibiotic therapy, and urgent surgical 
treatment is the only option in these cases. On the other hand, if infection is diagnosed early, it 
is possible to prepare the patient for surgery and reduce the manifestation of infection, which 
will improve clinical outcome.  
Surgical management includes graft excision with or without revascularization, as it is the 
foreign body, which intensifies the infection. Graft excision can be followed by extra-anatomic 
revascularization or in situ replacement of the graft (Table B). Complete debridement of the 
infected vascular graft and debridement of the surrounding infected tissues is one of the 
techniques, but this is usually performed with some limitation if the surrounding infected tissue 
area is large (15).  
Graft preservation as a surgical method has some limitations. It is indicated when infection 
involves autologous vein grafts, patches or infected prostheses which is made from 
polytetrafluoroethylene (PTFE) (18). Another condition when graft preservation can result in 
good clinical outcomes is that when patients do not have systemic septic symptoms, the 
infection develops in the early postoperative period (<4 months), infection is extracavitary, and 
no virulent microbiological species, such as MRSA or Pseudomonas aeruginosa or 
polymicrobial infection, have been found.   
Graft preservation and local treatment can be applied to patients with segmental contamination 
and anastomoses must be spared. The local treatment includes surgical wound sterilization to 
reduce bacterial colonization in the wound, multiple infected tissue debridement, temporary 
placement of antibiotic-loaded beads, rotational muscle flap or fasciocutaneous flap coverage, 
and use of irrigation suction drainage or vacuum assisted closure therapy. In cases with septic 
symptoms, which develop as consequences of local therapy that have been used to treat vascular 
graft infection, it should be considered that treatment with vascular graft preservation typically 
results in failure, and graft excision with or without revascularization should follow (17). In 
cases wherein the surgeon decides to perform vascular graft excision without revascularization, 
the patient needs to have adequate collateral circulation in the extremity.  
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Extra-anatomic bypass and In situ revascularization 
 
In situ revascularization is the main method of choice in patients with vascular graft infection 
and surrounding graft and tissue inflammation. In patients with septic symptoms, extra-
anatomic bypass surgery can also be considered. This type of surgery can be done in more than 
one stage. The advantage for such an approach is that the patient can much better tolerate small 
surgeries, which are done in a stepwise manner, instead of a single large surgical procedure, 
with significant blood loss and other intraoperative complications. Abraham et al. in their study 
discovered that a stepwise extra-anatomical bypass approach not only reduced blood 
transfusion requirements, but also decreased mortality rates and lower extremity amputation 
rates (2). In the stepwise graft infection surgery, there are some concerns that infection can 
cross to the newly implanted graft from the infected vascular graft. However, studies are 
presently unable to confirm such concerns, and thus, the approach has been safely used in 
vascular graft infection patients (62).  
In situ revascularization is one method that has been more and more popular nowadays. The 
advantages of in situ revascularization are a relatively short operation time and that it is 
technically easier to perform when compared with extra-anatomical bypass surgery. Moreover, 
in situ revascularization shows better clinical outcomes, reduced ICU days, reduced amputation 
rates, and lower mortality rates (71). 
In situ revascularization has often been used for prosthetic grafts, arterial allografts or 
autologous venous grafts. The advantage of arterial allografts and autologous vein grafts is that 
they show better results with regard to reinfection rates, as compared to prosthesis implantation, 
as the patient’s tissues have lower affinity to native tissues compared to foreign material.  
In cases where the infection affects the aortofemoral region, the use of the great saphenous vein 
(GSV) or superficial veins from the lower extremity is possible. However, autologous vein 
preparation takes extra time and is associated with operation prolongation. Another problem is 
that the GSV or the superficial veins used in ileo-femoral or aorto-iliac reconstructions results 
in low patency rates, due to diameter mismatch (82). 
The only disadvantage from this surgical method is that reinfection rates are potentially higher 
in patients with highly virulent microorganisms, such as Pseudomonas species or multiple 
microorganisms isolated from infected wounds. In such cases, in situ revascularization is not 
preferred.  
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Vacuum assisted wound closure  
Vascular infection management in the ileofemoral region includes different treatment methods. 
The two important vascular infection management methods include operative treatment and 
antibiotic treatment. In the last decade, vacuum assisted wound closure therapy (VAC) has 
become more and more popular as a treatment method, with good results (11).   
The VAC system, which can be used in cases of vascular graft infection, consists of inert 
reticulated open cell foam that needs to be adapted to the lower extremity wound. When the 
VAC foam is adapted to the wound, the VAC foam and the end of the wound need to be covered 
with a semi-occlusive film. Tubing needs to be attached to the VAC system via a small incision 
in the VAC foam, while the other end of the tubing system is attached to the VAC suction 
device. The suction device and configuration delivers negative pressure to the wound that can 
be administered in a continuous mode or in the intermittent mode (3).   
The effect of negative wound pressure therapy in vascular graft infection can be described in 
the various actions on which this type of therapy has impact. First of all, it has been shown in 
some animal studies of chronic wound healing problems that with the VAC system, bacterial 
contamination in the wound becomes significantly lower and bacterial growth and colonization 
are reduced after a few days. At the same time, the VAC system has a positive effect on the 
wound due to increased perfusion. Increased perfusion and better circulation decreases bacterial 
contamination and hastens wound healing. Micro-deformation of the wound surface and 
suction of the exudate, which develops in the wound, improves healing (6, 64). These 
mechanisms of the VAC system can explain why negative pressure therapy is better than wet 
to moist dressings. 
The effectiveness of VAC therapy versus standard dressings was shown in a study by 
Armstrong et al., who used this method in patients who underwent lower extremity 
amputations. One group of patients was treated with standard moist wound dressing, while the 
other group was managed with VAC therapy. The VAC group patients showed significantly 
lower hospital stay and a higher number of patients with completely healed wounds. The VAC 
group patients were also noted to have lower reoperation rates compared to standard moist 
wound dressing patients. In both groups, there were large numbers of patients who had 
amputation stump healing problems at the end of the study follow-up. The number of healing 
problems reached up to half of all patients included in the study. This indicates that there are 
some other unknown aspects affecting wound healing, and VAC therapy is not beneficial for 
all patients (7).      
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Irrigation suction drainage 
Irrigation suction drainage (ISD) is one of the therapy options that have been used historically 
to treat surgical wound infection. There are publications in different surgical fields, including 
vascular surgery, which analyze ISD therapy use in complex surgical site infections. Most of 
the publications are in the cardiac surgery field, for which this kind of therapy was used to treat 
sternal wound infections, with good results (30). The use of this therapy can also be seen in 
orthopedic and trauma surgery, but nowadays, this method has been frequently replaced by 
VAC therapy (63). There are published data that VAC therapy shows better results compared 
to ISD therapy in reducing mortality and hospital stay (9).  This type of therapy was used 
historically in vascular graft infection management with acceptable results, and many vascular 
surgery divisions are using this type of therapy nowadays. It should be noted that VAC therapy 
takes a more important role in vascular surgery, with good results, while ISD therapy, because 
of some restrictions such as wound area, remain to be the therapy of choice in lower extremity 
vascular graft infection.   
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Table B. Summary of vascular graft infection surgical management modified according to 
Thompson (99)  
Treatment option Manifestation Extent of infection Microbiology 
Graft 
preservation/local 
therapy 
Early infection, no 
sepsis 
Not Dacron, graft 
body only, no 
anastomosis, 
segmental 
Gram-positive, 
Staphylococcus 
species 
Graft excision only Graft thrombosis 
viable limb, 
adequate collaterals 
Any Any organism 
Excision and ex situ bypass 
Simultaneous 
excision and 
revascularization 
Unstable patient, 
hemorrhage, severe 
sepsis 
Invasive infection Any organism 
Staged excision and 
revascularization 
Stable patient, mild 
sepsis,  no active 
hemorrhage 
Invasive infection Any organism 
In situ replacement 
Prosthetic No sepsis Biofilm infection, 
segmental 
Staphylococcus 
epidermidis, 
negative Gram stain 
Autologous vein No sepsis, severe 
occlusive disease 
Invasive or biofilm, 
diffuse or segmental 
Not Pseudomonas 
species 
      
 
 
 
 
 
 
19 
 
Objectives 
The aim of this study is to include patients with lower extremity vascular graft infection, and 
to analyze risk factors, which could be associated with vascular graft infection. For all the 
patients included in the study, the vascular graft infection was managed either with the VAC 
system or the ISD system. 
The first objective was to compare both methods (VAC versus ISD) retrospectively to see if 
there is any significant difference in clinical outcome between the 2 methods.  
The second objective was to analyze treatment costs and economic benefits between the 2 
methods and to find out which method is more cost effective. 
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Materials and Methods 
Patients with lower extremity vascular graft infection that developed after vascular graft 
implantation in the ileofemoral region consecutively were included in this study.  This is a 
retrospective study, and includes patients in a 9-year time period, from year 2006 up to year 
2015. The follow-up period after primary ileofemoral vascular graft surgery was 1 year. In this 
time period, the patient history was analyzed for development of graft infection. If there was 
no infection diagnosed in the first year after operation, no future follow-up was done.  
If infection was diagnosed in the first year after initial operation, the patient’s medical history 
was analyzed in detail. The aim was to find possible preoperative risk factors, which could play 
roles in vascular graft infection development. We analyzed acute management after vascular 
graft infection was diagnosed, and follow-up after diagnosis of infection was 6 months. 
From 2006 up to 2015, Contilia Heart and Vascular Surgical Centre did 6232 lower extremity 
vascular reconstruction operations. We used a clinical diagnosis-related group (DRG) system 
to find patients with lower extremity vascular graft infection. From the ICD-10 (10th revision 
of the International Statistical Classification of Diseases and Related Health Problems) 
diagnostic coding system, we used the following codes to determine which patients have been 
diagnosed with vascular graft infection after the initial operation: 
T82.7 - Infection and inflammatory reaction due to other cardiac and vascular devices, implants 
and grafts 
T82.8 - Other specified complications of cardiac and vascular prosthetic devices, implants and 
grafts 
T82.9 - Unspecified complication of cardiac and vascular prosthetic device, implant and graft 
These codes and subcodes were used to filter the patient list and to identify patients with 
possible vascular graft infection. After filtration of the aforementioned codes and subcodes, the 
patient list included 1209 patients. The large patient count can be explained by patients who 
had infections in other localizations, as well as patients with vascular graft thrombosis, bleeding 
after initial operation, and aneurysm formation.  
Eight out of 1209 patients developed infections of the lower extremity vascular graft. These 
patients already had external vascular reconstructions  in another hospital or their vascular graft 
infection was already treated in other hospital. These patients were excluded from our study. 
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First of all, because the full medical histories of these patients are unavailable, and secondly, 
our goal was to analyze initial management after ileofemoral graft infection diagnosis. 
We did the analysis of all 1201 patients. We looked through the patients’ charts to determine 
the lower extremity vascular graft initial operation. After the initial operation date was found, 
we looked through patient charts in the 1-year period to find information about vascular graft 
infection. 
The time period 1 year after initial surgery was chosen because our goal was to standardize 
patient follow-up. As our study began in the year 2016, the patients who were included in the 
year 2015 were able to complete the minimum follow-up time. 
After the 1201 patients’ clinical histories were analyzed, we found 67 patients who were 
primarily included in our study. After primary analysis, we did a detailed patient clinical history 
analysis according to the following parameters. The rest 1134 patients did not correspond to 
our study criteria. Twenty-seven from 1134 patients had aortic infection, which not involved 
ileofemoral region. For this reason, they were not included in the study. 
We made a list of possible infection risk parameters based on literature review. We did a 
MEDLINE search with following criteria: “lower extremity vascular graft infection”, “vascular 
graft infection risk factors”, “femoral graft infection”, “ileofemoral vascular graft infection”.  
We excluded all non-English language publications, and all publications, which did not include 
peripheral lower extremity vascular graft infection. Publications with information about risk 
factors for vascular graft infection were included in our study to create our databases. From our 
Medline initial search, we found 1352 publications which, after looking through publication 
abstracts, were narrowed down to 26 publications that contained information about possible 
risk factors for lower extremity vascular graft infection. Based on these 26 publications, we 
made a risk factor database for peripheral vascular graft infection. Additionally, we included 
some data in our database, which could have an effect on infection development but has been 
rarely analyzed, such as electrolyte imbalance.    
In our database, we listed many possible risk factors, which include well-known risk factors 
such as atherosclerosis, and alcohol and nicotine consumption, as well as not well-published 
possible risk factors that have a negative effect on immunity, and as a result, can increase the 
risk of vascular graft infection. Such risk factors include other infections, renal insufficiency, 
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and orthopedic procedures with foreign material implantation on the ipsilateral side of the 
vascular bypass graft.  
After analysis of the patients’ histories, we found 4 patients with missing information that is 
necessary for our study. These patients were thus excluded from the study. 
The next important step was to find information about vascular graft infection management 
methods. Aside from information about reoperations, it was important for us to gather 
information about vascular graft infection treatment with VAC therapy or irrigation suction 
drainage (ISD) therapy. 
Since one important aim of this study was to analyze the economic benefit of the 2 management 
methods, we looked through the patients’ medical histories to determine which of the methods 
was used in the treatment process and additionally analyzed costs related to respective 
treatment. Of the 63 remaining subjects, 6 patients had no recorded information regarding the 
use of VAC therapy or ISD therapy in the patient history. For this reason, we excluded these 
patients from our study.    
Finally, 57 patients corresponded to all our criteria and were included in the study. From these 
patients, medical histories were collected, as well as data about possible risk factors, and 
information about intensive care unit (ICU) stay and hospital stay until discharge. Information 
about the initial operation and reoperation, was included for all 57 patients (Table C).  
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Table C: Study population 
 
  
6232 patients with lower 
extremity reconstruction 
surgery from 2006 up to 
2015 
1209 patients with 
vascular graft infection 
codes 
1201 patients with 
vascular graft infection 
codes 
8 patients 
with lower 
extremity 
vascular 
graft 
infection 
which was 
treated in 
other 
hospital 
 
67 patients with lower 
extremity vascular graft 
infection 
63 patients with lower 
extremity vascular graft 
infection 
4 patients with lower 
extremity vascular 
graft infection but 
missing data which 
are necessary for 
study 
 
1134 patients 
with vascular 
graft 
infection 
which not 
corresponded 
to our data 
57 patients with lower 
extremity vascular graft 
infection 
21 patients with lower 
extremity vascular graft 
infection who underwent 
ISD therapy 
36 patients with lower 
extremity vascular graft 
infection who underwent 
VAC therapy 
6 patients with lower 
extremity vascular 
graft infection 
treated without VAC 
or ISD therapy or no 
data about therapy 
 
5023 patients with 
lower extremity 
reconstruction 
surgery without 
complications 
 
27 patients 
with aortic 
vascular graft 
infection  
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The infection grade was classified according to the Szilagyi classification. The patients were 
classified in to 2 groups, according to which type of management – therapy (VAC or ISD) was 
applied.  
Owing to the fact that there are no specific criteria for vascular graft infection diagnostic, the 
patients with suspected clinical symptoms such as local pain, swelling, warmth or redness of 
the vascular graft wound, fever, or laboratory findings such as leukocytosis or increased 
infection markers with clinical correlate, as well as radiological imaging - computer 
tomography scan - were used as a criteria for vascular graft infection diagnosis and treatment 
initiation.     
For each patient diagnosed with vascular graft infection, bacteriological identification of the 
bacterial species causing the infection was done. In cases where there were different 
bacteriological species isolated from the infected wound, all pathogens were documented in 
our database. All 57 patients who were included in the study had bacteriological species isolated 
from the infected wound. 
Therapy with ISD or VAC was initiated when the patient had an ileofemoral vascular graft 
infection. This therapy was combined with surgery on the infected area and antibiotic 
management. The method utilized – whether ISD or VAC – was dependent on the decision of 
the surgeon. There were no specific internal standards in our division as to when ISD therapy 
or VAC therapy is   preferred. Usually it was decision from vascular surgeon on duty which of 
methods have been preferred.  The only contraindication to the ISD therapy was a large wound 
area when wound closure was not possible or a known suspected allergic reaction to the ISD 
components. In such cases, VAC therapy was preferred.   
The surgical intervention is known as the gold standard procedure for a vascular graft infection. 
The patients with diagnosed ileofemoral vascular graft infection underwent revision surgery in 
our Vascular Surgery Center. According to the grade of infection, patients underwent infected 
wound debridement, if infection involved dermis or subcutaneous tissues, or total infected 
vascular graft explanation with autogenous vein in situ replacement of infection with vascular 
graft involvement. Another option which was performed on infection with prosthesis 
involvement was extra-anatomical bypass with autogenous vein reconstruction (see Table D). 
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Table D.  Ileofemoral vascular graft infection management regarding the infection grade. 
 Irrigation drainage therapy 
Number of patients 
Vacuum- assisted closure 
therapy 
Number of patients 
Dermis and soft tissues 
debridement of vascular 
graft infection 
 
14 
 
22 
Debridement of soft tissues 
with infected vascular graft 
explantation and in situ 
reconstruction 
 
 
6 
 
 
11 
Debridement of soft tissues 
with infected vascular graft 
explantation and extra-
anatomical autogenous vein 
reconstruction 
 
 
1 
 
 
3 
 
Our clinical division has made internal guidelines for the use of ISD therapy. Thus, we have a 
standardized therapy approach for all ISD patients with vascular graft infection.  
ISD therapy was initially applied in the operation theater. If the patient is able to tolerate it, we 
perform the ISD application under local anesthesia. We used 1% mepivacaine to infiltrate the 
wound tissues. Our therapeutic concept includes taking bacteriological swabs for microbiology 
prior to irrigation of the infected wound. After swabbing, wound disinfection with liquid iodine 
was performed, followed by wound debridement of necrotic tissues if necessary. After the 
wound is irrigated, 2 drainages were placed in the wound. Usually, the first drainage size is 12 
Fr or 14 Fr, while the second drainage size is either a 16 Fr or 18 Fr. After drainage has been 
placed onto the wound, the wound was closed with surgical subcutaneous and cutaneous 
sutures. We normally use interrupted surgical sutures. After wound closure, we placed sterile 
dressing and connected the first drainage to 1 L of Natrium Chloride 0.9% (NaCl) bottle 
admixed with 60 ml of liquid iodine (Betaisodona® liquid). The second drainage was then 
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connected to a normal drainage bag. After this procedure, the patient can be moved from the 
operation theater to the vascular surgery ward or in severe cases when ISD was combined with 
infected vascular graft surgery, to the ICU. The infusion rate of the NaCl and iodine bottle is 1 
L in 24 hours. After 24 hours, the bottle was changed to a new one. The therapy time is 5 days. 
On day 6, we use only 1 L of NaCl 0.9% infusion. On day 7, we evacuate the drainage from 
the wound. Wound dressing changes were done daily. According to the protocol, the nurse will 
check the volume of the second drainage bottle twice a day to ensure that the irrigation suction 
system works and is not blocked. In the case of blocks or clotted drainage, we used a 50 ml 
NaCl 0.9% infusion pump syringe, which the nurse connects to the drainage in order to irrigate 
the system.     
The VAC system is another method of vascular graft infection management that we are using. 
The first procedure is VAC installation, which was performed in the operation theater. Change 
of VAC foam was likewise done in the operation theater. The initial VAC system installation  
was routinely combined with a debridement of necrotic wound tissue. Culture swabs were taken 
for microbiology before wound irrigation with saline liquid. After the microbiology has been 
taken, the necrotic wound tissues were surgically removed and adequate hemostasis achieved. 
Prior to application of the drape, we prepare the peri-wound skin, ensuring that the skin is dry 
and there are no sign of infected tissue. Skin densification around the surgical wound was done 
to clear the skin of perspiration, oil or body fluids that will make the skin moist. After the 
wound is prepared, the sterile open-cell foam dressing is placed into the wound cavity. The 
foam can be adapted to the wound by cutting it into the wound form. We used black foam, 
which is made from polyurethane ether (PU). The black foam has larger pores, is lighter, easily 
collapsible, and hydrophobic, with a pore size of 400 to 600 nm. After the foam is placed over 
the wound, we embedded in the foam a fenestrated evacuation tube, which was connected to a 
computer-controlled vacuum pump that contains a fluid collection canister. At the end of the 
procedure, the wound and peri-wound skin was sealed with an adhesive drape. We used double-
layered drapes, which are especially commercially designed for VAC therapy. The main point 
is that by applying the drape, we cover the following wound area: the foam and tubing, and at 
least 3 to 5 centimeters of surrounding healthy tissue. This ensures a seal. Our internal standards 
included changing the foam and drape every 72 to 96 hours. By changing the foam regularly, 
we were able to evaluate the wound condition and adherence to the wound bed was prevented. 
In cases of tissue adhesion, we used sterile NaCl 0.9% liquid to loosen the foam for removal 
from the wound bed and the peri-wound skin. Our standard included VAC system changes 
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under local anesthesia using 1% lidocaine solution. In cases where patients are unable to 
tolerate local anesthesia only, systemic pain reduction by the anesthesia team with remifentanil 
infusion was done. In worst cases, general anesthesia was applied for VAC system changes.  
The last step of VAC system installation included application of negative pressure on the 
surgical wound. We used the VAC pump option with continuous pressure normally in the range 
of 50 up to 100 mmHg. The pressure was set to continuous for the first 48 hours and was  
elevated as required thereafter. Continuous suction modus was routinely used in wound healing 
process.   
As our study included the economic benefits of VAC versus ISD therapy, we contacted our 
hospital finance department to find out the treatment prices for each of the therapy options. To 
make it simple, we noted only the costs, which are related to VAC drainage or ISD drainage 
therapy. That means we did not include costs, which are constant for both patient groups, such 
as hospital costs including ICU days, operation costs, personal costs, radiological 
microbiological investigation, etc. We presumed that these costs are equal for both patient 
groups. For this reason, we did our calculation based on the materials and medication costs, 
which were explicit only for VAC or ISD drainage therapy. We did not include anesthesia costs, 
as our primary standards included VAC and ISD system changes under local anesthesia. For 
the ISD system, there was no need to change the system itself, and only the bottle of irrigation 
liquid must be changed. Usually, ISD drainage evacuation can be done without anesthesia or 
under local anesthesia.    
The VAC or ISD drainage system set up was done in the operation theater. The irrigation liquid 
change was normally done in the ward. The VAC system change was done in the operation 
theater. We did not include operation time for both procedures because we could not specify 
the exact time needed for ISD or VAC system installation, as in addition to these system 
installations, there was usually  wound revision, or in some cases, vascular graft explantation 
performed at the same time. In addition, for many patients in both groups, this type of therapy 
was associated with wound debridement, as well as manipulation of the vascular graft, which 
required general anesthesia. 
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Statistical analysis 
Patients with vascular graft infections were identified using diagnosis-related group system 
(DRG), which was used in our hospital. For the patients’ medical history analysis, we used the 
Meierhofer AG (MCC) program, where all the patients’ medical charts have been saved 
electronically. The patient data was collected in Microsoft Excel 2010. For statistical analysis, 
we used the statistical analysis program IBM SPSS 22.0 version. We used descriptive statistical 
methods to analyze the basic features of our data. For the group population analysis, we used 
mean values and standard deviation. For categorical variables, we used the Chi square test and 
Fisher’s exact test. The level of significance was set at p< 0.05. The independent t-test, also 
called the two sample t-test or student's t-test, was used to determine whether there was a 
statistically significant difference between the means in the 2 unrelated groups. For the survival 
rates, we used Kaplan-Meier curves, which graphically showed survival rates in both patient 
groups. The medical treatment costs, which included VAC therapy and ISD therapy, were 
figured out through our finance department using the DRG system program.    
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Results 
The objectives of our study were to analyze possible risk factors for vascular graft infection, to 
compare vascular graft infection management options (VAC therapy versus ISD therapy), and 
to determine differences between the 2 methods and analyze the clinical outcome for each 
patient group. The second objective was to analyze both management methods in terms of costs, 
in order to find out which is the more cost-effective method.  
VAC versus ISD Group population characteristics 
In our study, we included 57 patients, who were divided into 2 groups: the ISD group included 
a total of 21 patients (7 female – 33%, 14 male – 66%), while the VAC group included 36 
patients (13 female – 36%, 23 male – 63%) (Figure 1). The mean age in the ISD group was 
66.7 years versus 71.3 years in the VAC group (Table 1). In the ISD group, mean height and 
weight were 166 cm and 86.2 kg in females, and 175.2 cm and 84.2 kg in males. The mean 
body mass index in the ISD group was 31.2 for females and 27.3 for males. In the VAC group, 
the mean height and weight were 161.6 cm and 71.9 kg in females, and 173.9 cm and 76.6 kg 
in males. The mean body mass index in the VAC group was 27.4 for females and 25.2 for males 
(Table 2). Based on the population characteristics, we did not find any statistical difference 
between the 2 groups (p>0.05). 
Szilagyi classification 
All patients included in the study were classified according to the Szilagyi classification. Grade 
I infection according to the Szilagyi classification was noted in 6 patients in the ISD group 
versus 8 patients in the VAC group. Grade II infection was seen in 8 patients in the ISD group 
versus 14 patients in the VAC group. Grade III infection was seen in 7 patients in the ISD group 
versus 14 patients in the VAC group (Table 3). There was no statistically significant difference 
between the 2 groups. 
Vascular graft localization 
In this study, we analyzed the anatomical locations of the infected vascular grafts in both 
groups. Ileofemoral bypass was performed in 8/21 patients in the ISD group versus 12/36 
patients in the VAC group. Femoropopliteal bypass was performed in 7/21 patients in the ISD 
group versus 13/36 patients in the VAC group. Much fewer were patients who underwent 
ileopopliteal bypass, which included 2/21 and 5/36 patients in the ISD and the VAC groups, 
respectively. Patients who underwent aortobifemoral bypass were 3/21 in the ISD group and 
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5/36 in the VAC group. Only 1 patient in each group underwent axillofemoral bypass (Figure 
2).  
Additionally, we analyzed if patients already underwent previous ipsilateral bypass in the 
operative region. In case with a history of previous ipsilateral bypass operation, the procedure 
is more challenging and operation time is longer, which correlates with graft infection 
development. Ipsilateral vascular bypass was performed in 4/21 patients in the ISD group and 
10/36 patients in the VAC group (Figure 3). There was no statistically significant difference 
between the 2 groups (p>0.05) with regard to this.  
We likewise noted information about any additional foreign material in the area of operation, 
as it can be a risk factor in elevating vascular graft infection risk. Majority of the patients (16/21 
in the ISD group, 21/36 in the VAC group) did not have any additional material in the operative 
area at the time of initial operation. Meanwhile, there were 4/21 patients in the ISD group and 
12/36 patients in the VAC group who had ipsilateral hip prosthesis. One patient in each group 
had osteosynthesis with a plate in the operative area, and 2 patients in the VAC group had hip 
osteosynthesis with dynamic hip screw (DHS fixation) (Figure 4). 
Amputation rates 
The amputation rates were calculated in both groups. Vascular graft infection resulting in lower 
extremity amputation occurred in 7/21 patients in the ISD group versus 10/36 patients in the 
VAC group. The p-value did not show statistical significance between the 2 groups (Table 4). 
Hospital stay 
We analyzed the length of hospital stay for both patients groups after vascular graft infection 
was diagnosed. We did explicit analysis of ICU days and normal vascular surgery ward days. 
In the ISD group, the mean hospital stay duration was 34.2 days versus 37.7 days for the VAC 
group. The mean ICU stay after ISD therapy was 4.9 days and 4.1 days after VAC therapy. 
There was no statistically significant difference seen between the 2 groups in the length of ICU 
or ward stay (Table 5). 
Additionally, we did analysis of the time period of the VAC and ISD therapies. The mean ISD 
therapy duration was 7.2 days (from 7 days up to 8 days), while mean VAC therapy duration 
was 14.8 days (from 7 days up to 24 days) (Table 6). This was a statistically significant 
difference between the 2 groups (p<0.01).  
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Bacteriology 
There are different bacteriological species isolated from the infected wounds. One of the most 
common species in both groups was methicillin-resistant Staphylococcus aureus (MRSA). In 
the VAC group, there were 15 patients with isolated MRSA infection versus 3 patients in the 
ISD group, this shows statistically significant difference between groups (p<0.05). The most 
common bacteriological species isolated in the ISD group was Staphylococcus aureus, which 
was found in 7 patients versus 9 patients in the VAC group. The other bacteriological species 
were isolated only for 1 to 3 patients, and can be seen on Table 7. 
Antibiotic therapy 
We analyzed  antibiotic therapy preoperatively and intraoperatively during the initial operation, 
as well as antibiotic therapy during ISD or VAC initiation. We were able to find out antibiotic 
therapy using patient charts and anesthesiology protocols.  
In the ISD group, 3 patients were already being given antibiotics before the initial operation 
versus 4 patients in the VAC group. The 2 patients in the ISD group who were being given 
antibiotics preoperatively had other active infections, elevated infection parameters or 
immunosuppressed conditions. In the VAC group, we were not able to find such correlation 
(Table 8). 
During vascular bypass graft operation, all patients perioperatively received a single 
intravenous shot of antibiotic. In the ISD group, 20 patients received Cefuroxime and 1 patient 
received Sulbactam/Ampicillin because of open peritoneum (peritoneal incision during 
preparation). In the VAC group, the tendency was similar, with 33 patients receiving 
Cefuroxime, 1 patient receiving Sulbactam/Ampicillin because of open peritoneum, and 2 
patients receiving Clindamycin because of allergic reaction to Penicillin (Table 9). 
The antibiotic therapy given upon initiation of the ISD or VAC therapy was decided according 
to the patient’s bacteriological results or antibiogram, or if there was no information about 
bacteriological status, broad-spectrum antibiotic therapy was initiated. Cefuroxime was 
continued as antibiotic in 10/21 patients in the ISD group versus 16/36 patients in the VAC 
group. Vancomycin was given to 5/21 patients in the ISD group versus 14/36 patients in the 
ISD group, because of MRSA in bacteriology results, or according to the patient’s clinical 
history when bacteriology was not available. Detailed antibiotic therapy is shown in Table 10. 
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Clinical outcome 
The clinical outcome showed no statistical difference between the 2 groups. There were 4/21 
patients in the ISD group who were transferred directly to a rehabilitation clinic versus 12/36 
patients in the VAC group. In the ISD group, there was 1 patient who was transferred to another 
hospital due to non-medical reasons. In the ISD group, 14/21 patients were discharged from 
hospital versus 21/36 patients in VAC group. The mortality rate was 2/21 patients in the ISD 
group versus 3/36 patients in the VAC group. Detailed information is shown in Figure 5. 
Blood transfusion 
The blood transfusion rates between the 2 groups show no statistical difference. We analyzed 
blood transfusion requirements during the operation and in the first 48 hours after surgery. 
During the operation, the average transfused amount was 0.76 units in the ISD group compared 
to 0.58 units in the VAC group.  
After ISD or VAC therapy was initiated, an average of 2.14 units of blood versus 1.67 units 
were transfused within the first 48 hours (Table 11). It must be noted that VAC and ISD therapy 
initiation was often combined with revision operation. 
In the ISD group, 13/21 patients required blood transfusion during the operation or within 48 
hours after surgery, compared to 24/36 patients in the VAC group (Table 12). 
Risk factors for vascular graft infection 
We did analysis of possible vascular graft risk factors for patients with vascular graft infection. 
The risk factors included in our analysis must have already been present before the initial 
vascular graft infection. We looked at both groups to see how many of the patients had certain 
risk factors and analyzed them to see if there were differences in certain risk parameters 
between the 2 groups. 
The risk factors which we analyzed included non-insulin dependent diabetes mellitus and 
insulin dependent diabetes mellitus, which was present in 9/21 patients in the ISD group and in 
14/36 patients in the VAC group. There was likewise no statistically significant difference 
(p>0.05) between the groups if the parameter used was diabetes in general, i.e. a combination 
of insulin dependent and non-insulin dependent diabetes mellitus. 
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Renal insufficiency was diagnosed for 5/21 patients in the ISD group and 6/36 in VAC group. 
From those patients, 3 patients in the ISD group and 2 patients in the VAC group had terminal 
renal insufficiency, which required dialysis therapy. 
Liver failure rate was low and was diagnosed in 2 patients in the ISD group and in 1 patient in 
the VAC group.  
Alcohol and nicotine abuses were 2 factors, which played important roles in vascular graft 
infection development. According to our data, 8/21 patients had histories of alcohol abuse in 
the ISD group and 11/36 in the VAC group. There was no difference between the groups. 
Meanwhile, nicotine abuse history was positive for 15/21 patients in the ISD group and 24/36 
patients in the VAC group. 
The respiratory diseases we analyzed included 2 common respiratory illnesses - bronchial 
asthma and chronic obstructive bronchitis. The other pathological conditions related to the 
lungs were rare and involved only a few patients; we opted not to do analysis of these 
conditions. Bronchial asthma was present in only 1 case in the VAC group, while chronic 
obstructive bronchitis was present in 10/21 patients in the ISD group and in 16/36 patients in 
the VAC group. 
Cerebrovascular disease is 1 of the additional parameters, which we analyzed to get a general 
impression about risk factors. Cerebrovascular disease was diagnosed in 7/21 patients in the 
ISD group versus 11/36 in the VAC group. 
Urinary tract infection was rarely present, with only 2 patients in the ISD group and 1 patient 
in the VAC group with this condition. 
In the all of analyzed risk factor parameters, there was no statistically significant difference 
between the 2 groups. The summary of risk factors is shown on Table 13. 
Diabetic foot ulceration is one of the factors related to vascular graft infection. In this study, 
the number of patients who presented with foot ulcers was very small. We analyzed diabetic 
foot ulceration according to the Wagner-Meggitt classification (50). All patients had grade 0 
up to grade 2 diabetic foot, according to Warner-Meggitt. No patients had grade 3 up to grade 
5 ulcers in either group. Diabetic foot ulceration was diagnosed in 7 patients in the ISD group 
versus 3 patients in the VAC group. Because of the small number of patients, we did not do 
explicit analysis for each diabetic foot grade. There was no statistical difference between the 
groups (Figure 6). 
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Immunosuppression or immunosuppressive medications prolong the healing process and are 
important risk factors for wound infection. In both analyzed groups, there were only 2 patients 
who were immunosuppressed at the time of initial operation or when ISD or VAC therapy was 
began. Both patients who had vascular graft infection and immunosuppression were in the VAC 
group. One female patient had a history of the chemotherapy for invasive breast carcinoma. 
This patient presented with acute occlusion of the femoral artery, and for this reason, underwent 
vascular graft operation. The other patient had the same history of acute ileofemoral occlusion, 
but the patient was on radiation therapy due to oropharyngeal carcinoma. No patients in the 
ISD group had immunosuppression. 
For endocrine disorders, we analyzed 2 conditions, which play roles in vascular graft infection 
– hypercholesterolemia and hypolipoproteinemia.  
Hypercholesterolemia was a common disorder in both groups, and was diagnosed for 11/21 
patients in the ISD group and 19/36 patients in the VAC group. Almost identical results were 
seen for hypolipoproteinemia, with 10/21 patients in the ISD group and 19/36 patients in the 
VAC group having this condition. There was no statistical difference between the groups 
(Figure 7a and Figure 7b).  
The other endocrine disorder we analyzed was malnutrition. It has been described as a risk 
factor for vascular graft infection development and prolonged healing process. The number of 
patients with malnutrition was small – 1/21 patients in the ISD group versus 4/36 patients in 
the VAC group. We did not find any statistical difference between the groups with regard to 
malnutrition.  
Operation time 
We also did analysis of the operation time. As most of the operations involved combined 
surgical management, which included revision operation and VAC or ISD therapy initiation at 
the same time, we decided to analyze common operation time. The operation time ranged from 
70 up to 320 minutes, with an average operation time of 167 minutes in the ISD group. For the 
VAC group, operation duration ranged from 56 up to 280 minutes, with an average time of 155 
minutes, with no statistically significant difference between the groups (Table 14a).  
The operation time for VAC system change every 72 hours was also analyzed. The operation 
duration ranged from 25 up to 105 minutes, with an average of 54 minutes (Table 14b).  
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Laboratory results 
 Laboratory parameters included serum sodium and potassium levels at the time of initial 
operation. The hypothesis was that electrolyte imbalance can play a role in vascular graft 
infection development. The other parameters we analyzed at 3 time points included levels of 
hemoglobin, leucocytes, and C-reactive protein. The 3 time points included before the initial 
vascular graft surgery, before the initiation of the VAC or ISD therapy, and before discharge 
from clinic, or in cases of death, the last available laboratory parameters. 
Before vascular graft operation, 15/21 patients in the ISD group had normal sodium levels 
versus 27/36 patients in the VAC group. Hyponatremia was present in 6/21 patients in the ISD 
group and 9/36 patients in VAC group (Table 15). The mean sodium level in the ISD group 
was 138 mmol/L (minimum 131 mmol/L up to maximum 145 mmol/L). In the VAC group, 
mean sodium level was 137 mmol/L (minimum 128 mmol/L up to maximum 144 mmol/L). 
Potassium levels before vascular graft operation in the ISD group were normal for 19/21 
patients; 1 patient presented with hyperkalemia and another patient presented with 
hypokalemia. In the VAC group, 33/36 patients presented with normal potassium levels, while 
3/36 patients presented with hyperkalemia (Table 16). The mean potassium level in the ISD 
group was 4.4 mmol/L (minimum 3.4 mmol/L up to maximum 5.6 mmol/L) versus 4.3 mmol/L 
(minimum 3.6 mmol/L up to maximum 5.7 mmol/L) in the VAC group.  
Total leucocyte level (normal range from 4.4 x 109/L up to 11.3 x 109/L) was analyzed initially 
before vascular graft surgery, with a mean level of 10.98 x 109/L (range from 3.97 x 109/L up 
to 31.35 x 109/L) in the ISD group versus 9.41 x 109/L (range from 4.00 x 109/L up to 16.40 x 
109/L) in the VAC group. 
The total mean leucocyte level at the time of ISD or VAC therapy initiation was 19.14 x 109/L 
(range from 10.75 x 109/L up to 34.98 x 109/L) in the ISD group versus 17.01 x 109/L (range 
from 7.24 x 109/L up to 30.47 x 109/L) in the VAC group. 
The mean total leucocyte level at the time of discharge from clinic in the ISD group was 10.37 
x 109/L (range from 5.18 x 109/L up to 24.00 x 109/L) versus 10.37 x 109/L (range from 4.35 x 
109/L up to 21.10 x 109/L) in the VAC group (Table 17). 
The hemoglobin level (normal range from 11.1 g/dl up to 16.4 g/dl) was analyzed initially 
before vascular graft surgery, with a mean level of 12.8 g/dl (range from 8.8 g/dl up to 16.7 
g/dl) in the ISD group versus 11.8 g/dl (range from 7.0 g/dl up to 17.4 g/dl) in the VAC group. 
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The hemoglobin level at the time of ISD or VAC therapy initiation was 8.5 g/dl (range from 
6.1 g/dl up to 11.5 g/dl) in the ISD group versus 8.4 g/dl (range from 6.5 g/dl up to 12.5 g/dl) 
in the VAC group. 
The mean hemoglobin level at the time of discharge from clinic was 10.8 g/dl (range from 7.4 
g/dl up to 14.1 g/dl) in the ISD group versus 10.5 g/dl (range from 8.0 g/dl up to 13.7 g/dl) in 
the VAC group (Table 18). 
The C-reactive protein (CRP) levels (normal range is <1.0 mg/dL) were analyzed before 
vascular graft surgery, with a mean level of 6.8 mg/dL (range from 0.1 mg/dL up to 33.6 mg/dL) 
in the ISD group versus 2.4 mg/dL (range from 0.1 mg/dL up to 27.7 mg/dL) in the VAC group. 
The CRP levels at the time of ISD or VAC therapy initiation was 21.7 mg/dL (range from 9.4 
mg/dL up to 44.9 mg/dL) in the ISD group versus 22.0 mg/dL (range from 1.2 mg/dL up to 
47.0 mg/dL) in the VAC group. 
The mean CRP levels at the time of discharge from clinic in the ISD group was 4.4 mg/dL 
(range from 0.2 mg/dL up to 31.5 mg/dL) versus 3.7 mg/dL (range from 0.1 mg/dL up to 21.4 
mg/dL) in the VAC group (Table 19). 
Patients with multiple infections 
The presence of another infection, whether chronic or acute, usually decreases immunity and 
can be one of the risk factors for vascular graft infection development. We checked if the patient 
has another infection present at the time when ISD or VAC therapy was initiated.  In both 
groups, there were 4 patients who had another infection present when ISD or VAC therapy 
began. We did not perform detailed analysis of infection status because of the small number of 
patients. The most common infection was respiratory airway infection or chronic respiratory 
airway infection exacerbation, which was present in 2 patients in the ISD group versus 3 
patients in the VAC group. two patients in the ISD group had urinary tract infection versus 1 
patient in the VAC group (Table 20).  
VAC versus ISD therapy failure 
Our analysis included initial ISD or VAC therapy failure. Therapy failure was defined as the 
use of other additional vascular graft infection management methods, as well as repeat VAC 
therapy, or in case of ISD failure, initiation of VAC therapy. In cases of failure, we no longer 
analyzed the effect of subsequent VAC therapies or other management methods. In both groups, 
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there were 3 patients who did not experience any beneficial effect from the initial VAC therapy 
or ISD therapy. In fact, in the ISD group, 2/3 patients with therapy failure died at the end of the 
therapy, while in the VAC group, 3/3 patients with initial therapy failure died. One patient who 
developed ISD failure was subsequently managed with VAC therapy. 
VAC versus ISD economical aspect 
We analyzed the ISD and VAC therapy costs after therapy initiation. Calculation of material 
costs were done for 2 periods – 1 week after beginning therapy, and a 3-week period.  
Because VAC therapy duration can last up to 3 weeks, we calculated costs for a maximum 3-
week time period, to show the economical difference between both therapy costs.  
The therapy costs were based on material costs for a 1-week period for the ISD therapy and for 
a maximum of 3 weeks for the VAC therapy.  
In the ISD group, the initial material equipment and costs were 20.50 € per patient. The used 
material and material costs are summarized in Table 21. Daily material costs without personal 
costs were 4.36 € (day 2 to day 5). The material costs on day 6 included only NaCl irrigation, 
and on day 7, drainage was removed. Total costs of the ISD therapy was 38.83 €. 
The initial VAC therapy costs depended on the surgical wound area. Based on surgical wound 
area, 3 calculations were done - for small surgical wounds with a size of 10 cm x 8 cm x 3 cm, 
medium wounds 20 cm x 12.5 cm x 3 cm, and large wounds 25 cm x 15 cm x 3 cm. The therapy 
initiation of small wounds costs 276.08 €, medium wounds 287.91 €, and large wounds 293.44 
€ (Table 22). 
The Contilia vascular division standard included VAC system changes every 3 to 4 days. As 
the VAC system can be used for up to 21 days, the calculations were performed for a 1-week 
and 3-week time period. The material costs for VAC system change for small wounds were 
73.32 €, medium wounds 79.06 €, and large wounds 84.60 € (Table 23). At the end of the 
therapy, the wound was closed; the material costs for wound closure was 13.99 € (Table 24).   
The costs between the groups for lower extremity infected vascular graft therapy showed a 
statistically significant difference (p<0.05). For a 1-week period, the difference between the 
ISD and VAC therapies were 324.56 € for small wounds, 342.13 € for medium wounds, and 
353.02 € for large wounds (Table 25 and Figure 8).  
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Moreover, if VAC therapy was continued for 21 days, the material costs for the VAC therapy 
increased dramatically in comparison with the ISD therapy. If the patient’s VAC therapy was 
done for 3 weeks, the material costs reached 729.99 € for small wounds up to 815.03 € for large 
wounds (Table 26 and Figure 9). Patients need to add hospital stay costs, personal costs, and 
VAC system change costs, as well. That all results in a much more expensive therapy cost if 
VAC therapy is used. However, VAC therapy may be performed for patients with more serious 
vascular graft infections with larger operative wounds, and management of such patients per se 
costs more than management of patients with not so serious vascular graft infections.  
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Discussion 
Lower extremity vascular graft infections are not very common. The management of an 
infected vascular graft can be very challenging, and usually requires multiple management 
methods and a multidisciplinary approach, which requires large expenses.  
Lower extremity vascular graft infection rates are 1% up to 5%, based on different studies (22, 
49). Our department results were very similar: from 6232 patients who underwent lower 
extremity vascular graft surgery, 67 patients developed vascular graft infection, which is 
1.07%. The downside is that we reviewed the patient’s histories only for a 12-month period; 
thus, it is theoretically possible that there are cases of late vascular graft infection that we 
missed. 
Different classification methods have been used to classify vascular graft infection grade. The 
two most popular classification methods are the Szilagyi and Samson classification. The 
Szilagyi classification is not as detailed when compared with the Samson classification, which 
analyzes the infected area in a more detailed manner, with conventional treatment for Samson 
classification grades 1 and 2, and surgical treatment for Samson grades 3 and 4 (80).  
Krejči et al. in their study analyzed patients with inguinal vascular graft infection, and to 
classify patients, they used the Szilagyi classification. In their study, 75% of all patients were 
Szilagyi grades I and II and 25% of patients were Szilagyi grade III (57). One other study from 
Dosluoglu et al. showed Szilagyi grade III in 46% of all cases and Grade II and I in 54% of 
cases (32). This shows how broad the variety of vascular graft infection is. In our study, Szilagyi 
grades I and II were seen in 66.7% of patients in the ISD group 61.1% of patients in the VAC 
group. Grade III infection was noted in 33.3% of the ISD group and 38.9% of the VAC group. 
These corresponds to average results compared to other studies. 
Amputation rates in lower extremity vascular graft infections differs a lot in the published 
studies. The reason for that is its multifactorial nature, which influences amputation rates. Sousa 
et al. analyzed 18 patients who developed vascular graft infection after femoropopliteal bypass 
surgery in the time period from 2007 up to 2012. In the study, amputation rates were as high as 
55% (91). Another study done by Acosta et al. analyzed amputation rates using different 
management aspects - patients with vascular graft infections who underwent VAC therapy as 
a treatment method. In the 7-year period, they included 37 patients with lower extremity 
vascular graft infections, with a follow-up time of 15 months. All patients underwent VAC 
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therapy and resulted in amputation rates of 33% (3). In other studies, amputation rates depended 
on the time after initial graft operation, and on infection development and management options; 
all these aspects resulted in amputation rates, which ranged from 18 up to 53% (13, 94).  
Our amputation rates showed similar results. In the VAC group, amputations rates reached 
27.8%, while in the ISD group, it was 33.3%. The study of Acosta et al. and our study clearly 
showed the benefit of VAC or ISD therapy in vascular graft infection management.  
Our study population had a mortality of 5/57 patients. The 2 patients who underwent ISD 
therapy management died at the end of therapy. One patient who underwent ISD therapy had 
therapy failure and was switched to VAC therapy. The 3 patients in the VAC group died during 
the therapy period or at the end of therapy, which showed similar results to the study of 
Svensson, with a 66% mortality in failure cases. Overall mortality in our study was 
approximately 10% in all included patients, which correlates with other published studies.  
There were 14/21 patients in the ISD group and 21/36 patients in the VAC group who were 
discharged from hospital after successful treatment.  These patients were evaluated in outpatient 
department, however follow up period differs a lot, and we could not exclude situation that 
some of patients continuing they follow up in other hospitals.  
There are a wide spectrum of a microbiological species, which induce vascular graft infections, 
which means that broad-spectrum antibiotic therapy needs to be initiated in cases of infection, 
if the agent is not known. Calligaro et al. in their study analyzed 141 patients with lower 
extremity vascular graft infection. As in this retrospective study, patients were collected from 
over a 15-year period, and analyzed microbiological variability for early and late vascular graft 
infections. The most frequently isolated bacteria were Staphylococcus aureus and 
Pseudomonas aeruginosa. Other common bacteriological species included Staphylococcus 
epidermidis, Streptococcus faecalis, Proteus species, and Escherichia coli (16). Another study 
done by Siracuse et al. analyzed 19 patients in series in a 10-year period. The most common 
isolated bacteria included Staphylococcus epidermidis (37%), Staphylococcus aureus (26%), 
Enterococcus species (10%), and MRSA (5%) (84). 
There is an increasing tendency for MRSA to induce vascular graft infection, especially in the 
last decade. Herrera et al. reported that the most common bacteriological species isolated from 
graft infection included Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia 
coli, and MRSA (44).   
41 
 
In our study, we had equal tendencies. In the VAC group, the most common isolated bacteria 
was MRSA, Staphylococcus aureus, and Enterococcus faecalis. In the ISD group, the 2 most 
common isolates were Staphylococcus aureus and MRSA. Pseudomonas aeruginosa was 
isolated in 2.8% of cases in the VAC group and in 9.7% of all cases in the ISD group.  
Basically, our study showed that MRSA is continuing to become a more frequently isolated 
organism from infected vascular graft wounds. The frequency of other bacteria showed the 
same kind of results as the literature. 
Antibiotic therapy is always a widely debated topic, especially in the last decade, because of 
rising resistance against antibiotics. Before the initial operation, all patients were given a single 
shot of the antibiotic Cefuroxime, or in the case of penicillin allergy, Clindamycin. Cefazolin 
is another antibiotic of choice because Staphylococcus aureus and Streptococcus epidermidis 
are common infectious agents (53). In the study by Hasselgren et al., they analyzed the effect 
of Cefuroxime. Significantly reduced surgical site infection was shown compared to the 
placebo group (43).   
In cases of vascular graft infection development, escalation of antibiotic therapy is usually 
done. Our aim was to give antibiotics according to the bacteriological results and antibiogram; 
however, results from the laboratory were not always readily available. In most of the cases, 
the commonly used antibiotic was Cefuroxime, used in 44.4% of the VAC group and 47.6% of 
the ISD group. This antibiotic was used as a single shot antibiotic for the initial operation, as 
its antibiotic spectrum covers most of the common bacterial species causing vascular graft 
infections. The second most common antibiotic in both groups is Vancomycin, used in 38.9% 
of the VAC group and 23.8% of the ISD group, which correlated with the bacteriological results 
from our study – 14.3% MRSA isolates in the ISD group and 41.7% MRSA isolates in the VAC 
group (p<0.05). This is the only statistically significant difference between groups in 
bacteriological analysis. After diagnosis of vascular graft infection, Vancomycin was given to 
patients with specific risk factors, such as long hospital stay prior to operation or MRSA 
infection in other locations.    
Erb et al. reported a series of 10 patients with peripheral vascular graft infection. Empirical 
antibiotic therapy included administration of Amoxicillin clavulanate in 70% of all cases, and 
Ceftriaxone in 20% of cases. In this study, Vancomycin was not used as empiric therapy (34). 
A Penicillin group antibiotic, especially Piperacillin/tazobactam, which covers anaerobes and 
Bacteroides fragilis, is recommended as the therapy of choice for these patients (78). There 
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have been controversial discussions about the use of carbapenem antibiotic in cases of vascular 
graft infections, because of the rising number of carbapenemase-producing Enterobacteriaceae 
(69). Hodgkiss-Harlow et al. did analysis of surgical site infection in aortic surgery. They 
reported an increase in number of MRSA infection in the last decade. In this study, similar to 
our study, their preferred primary antibiotic is a first or second generation cephalosporin. 
Additionally, they suggested coverage of MRSA in case of infection develops. In our 
institution, for most cases, we used Vancomycin or Linezolid to cover for MRSA; others, such 
as Hodgkiss-Harlow et al., prefer Daptomycin as the antibiotic of choice, because it produces 
rapid, concentration-dependent bactericidal activity to all Gram-positive bacteria, including 
MRSA, and controversially, shows better results in penetrating bacteria biofilms and killing 
bacteria in stationary-phase growth compared to Vancomycin and Linezolid (46).     
Red blood cell (RBC) transfusions were analyzed in 2 aspects: during VAC or ISD therapy 
initiation, and within 48 hours after the VAC or ISD therapy was initiated. The RBC 
transfusions during the operation were associated with bleeding when VAC or ISD therapy 
initiation was combined with large infected wound debridement and surgery on the infected 
vascular graft. However, many patients who receive RBC transfusions already had a low 
hemoglobin level initially. This can be explained by many factors, with one of the main factor 
being infection or septic complications after initial vascular graft surgery, which is associated 
with lower hemoglobin levels. The other factors for anemia are initial vascular graft surgery 
and its association with loss of blood, volume therapy, and the systemic inflammatory response. 
There are not many studies that analyze RBC transfusions in the setting of VAC or ISD therapy 
initiation. Moreover, there are no studies available that analyze RBC transfusion rates specific 
for lower extremity vascular graft infection management with VAC or ISD therapy. There are 
some general studies from cardiac surgery that report controversial opinions, stating that VAC 
therapy is associated with higher hemolysis and resulting in larger RBC transfusions 
postoperatively (24). On the other hand, other studies report that there are no differences with 
regard to hemolysis in patients with VAC drainage or ISD therapy (58).  
The study from O’Keeffe et al. is one of the few studies that analyze RBC transfusions in lower 
extremity vascular surgery. Unfortunately, this study reported about primary operations, and 
not about transfusion management related to vascular graft infection reoperation using VAC or 
ISD therapy. They reported on the correlation between RBC transfusion and increased 
morbidity and mortality postoperatively. Moreover, in the cases of low hemoglobin level of 7 
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g/dl but with no active bleeding, there has been no evidence that RBC transfusion will give 
patients the benefit of faster recovery (73). In our study, before initial vascular graft operation, 
mean hemoglobin level was 12.8 g/dl and 11.8 g/dl in the ISD and VAC groups, respectively. 
The average hemoglobin level at the time of VAC or ISD therapy initiation was 8.5 g/dl. Our 
division hospital anesthesia team usually begins RBC transfusion if hemoglobin level is ≤8 
g/dl. The hemoglobin decrease during the operation or postoperatively was obviously 
multifactorial; one of main reasons is intraoperative volume therapy and hemodilution. The 
persistent anemia preoperatively before revision operation in combination with VAC or ISD 
therapy explains why high blood transfusion rates are over 60% in both groups.  
Previous vascular graft bypass operations and future revision operations or vascular graft 
bypass reoperation definitely is challenging, because of surgical difficulties and increased 
operation time, which is associated with increased risk of vascular graft infection. In our study, 
14/57 patients already had a previous vascular graft bypass operation. These patients had longer 
operation times, which correlates with longer exposure of the open surgical wound to the 
environment, possible hypothermia during the procedure, and inadequate dosage of antibiotics. 
These are important factors that increase the risk of vascular graft infection development (38). 
As mentioned, we analyzed the patient’s clinical histories to find out possible infection risk 
factors. As this topic has been widely discussed in many publications, we analyzed some well-
known risk factors and added several extra factors, which could possibly have influence in 
vascular graft infection development.  
There are some publications that say that the risk for vascular graft infection increases if a 
patient has had previous surgery with implantation of foreign material in the vascular graft 
operation site. In our study, we did not find any statistically significant correlation between 
both groups related to previous surgery with implantation of foreign material. However 
according to the study population 20/57 patients who had foreign material implanted, 
developed vascular graft infections (29, 100). 
Endocrine disorders, such as hypercholesterolemia and hypolipoproteinemia, usually have a 
negative effect, not only to the normal vascular system, but also to implanted vascular grafts. 
Walton et al. in 1986 reported about lipid deposition in the vascular graft, which resulted in 
graft stenosis and calcification, and vascular graft aneurysm formation (106). The other study 
which showed the negative effects of hypercholesterolemia and hypolipoproteinemia is the 
study of Abbruzzese et al., where they analyzed the benefit of statin therapy in patients after 
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inguinal vascular graft operation. This study included 172 patients who underwent vascular 
graft surgery, and the subjects were divided in to 2 groups. The group given statin therapy 
showed 3.2 times better graft preservation compared to the control group (1). This confirms the 
harmful effect of hypercholesterolemia and hypolipoproteinemia on vascular graft walls.  
In our study, patients in both groups with confirmed diagnosis of hypercholesterolemia and/or 
hypolipoproteinemia were already started on statin therapy before or after surgical vascular 
graft implantation. Our study showed that hypercholesterolemia was diagnosed before initial 
vascular graft surgery in 47.6% of the ISD group and in 52.8% of the VAC group. 
Hypolipoproteinemia was diagnosed in 52.4% of patients in the ISD group and 52.8% of 
patients in the VAC group. These results were better than those of the study by Hirsch et al. 
They report that hypercholesterolemia was present in more than 60% of all patients with PAD; 
however, it should be mentioned that their study analyzed PAD patients, not those who 
underwent vascular graft surgery specifically (45). 
Hospital lengths of stay differ depending on the treatment options used to treat vascular graft 
infection. The length of hospital stay does not differ from data published in other studies. In 
previous studies, hospital length of stay varies depending on the infection grade, other 
comorbidities, and the isolated bacteriological species. For this reason, the hospital stay varies, 
from a median of 45 days up to 85 days (32). Most of the patients’ average length of hospital 
stay was 51 days (10, 102). Our study shows lower than average hospital lengths of stay, with 
an average of 34.2 hospital days in the ISD group and 37.7 days in the VAC group. This is 
comparable with other studies that used VAC therapy for vascular graft infection treatment. 
The analysis of ISD therapy and its impact on the length of hospital stay was not possible, as 
there are no studies, which analyzed length of hospital stay using ISD therapy for inguinal 
vascular graft infections. 
The VAC therapy duration was 14.8 days. This was similar to other studies, with average VAC 
therapy duration of 16 days up to 21 days (10, 102). 
Vascular graft infection factors are multivariable, and in many cases, the presence of multiple 
factors can increase the risk of infection development. However, there are some risk factors 
that are more frequently seen in patients with vascular graft infections.  
It is important to point out that risk factors need to be separated into 2 categories – the risk 
factors for PAD development, and the risk factors for vascular graft infection, which develops 
after the operation. It is also necessary to mention that there are some of risk factors, which can 
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affect PAD development, as well as play a role in vascular graft infection development. Such 
factors include atherosclerosis and hypercholesterolemia, diabetes mellitus, and 
immunosuppression, which prolongs the healing process and decreases immune response to 
bacterial colonization. Other risk factors that have an influence on vascular graft infection 
development after surgical intervention are operation length, perioperative antibiotic therapy, 
operation field disinfection, and the size of the operation field (83). 
Diabetes mellitus is a very common disorder that damages the blood vessel wall and also has 
an effect on vascular graft infection development, not only in the short term, but also in the 
long run. Our study showed that 9/21 (42%) patients in the ISD group and 14/36 (38%) patients 
in the VAC group had diabetes. Other studies that have analyzed vascular graft risk factors 
have shown similar results. The study of Siracuse et al. showed that diabetes mellitus was 
diagnosed in 230/460 patients who received lower extremity vascular graft operations for PAD 
(90). Another study by Mirzaie et al. which analyzed aortofemoral vascular graft infection 
showed that diabetes mellitus before initial vascular graft operation was diagnosed in 45.4% 
male patients and 18.1% of female patients. This study showed a difference in gender, which 
can be explained by the small number of patients included in the study (11 patients) (65). 
Diabetes mellitus plays an important role on the development of vascular graft infection, as 
confirmed by the study of Koutsoumbelis et al., where they analyzed and confirmed that 
diabetes mellitus has a negative effect on a patient’s immunity, increasing the risk for surgical 
site infection development, as well as increasing the time for surgical wound healing (56).  
Another factor that plays an important role is renal insufficiency. There are no clear 
pathophysiological mechanisms on how renal insufficiency can affect PAD development, and 
in the case of surgery, how renal insufficiency increases the risk of infection. One hypothesis 
is that renal insufficiency has a negative effect on the cardiovascular system, with 
atherosclerosis formation and vascular remodeling. The association with atherosclerosis is 
well-documented as one of the main risk factors for PAD. Another mechanism that could have 
a negative effect include increased inflammation biomarker production by patients with renal 
insufficiency. Biomarkers, such as C-reactive protein or interleukin-6, play a role in 
atherosclerosis development and development of PAD. Future detailed studies need to be done 
in order to understand the effect of renal insufficiency on vascular graft infection development 
after surgery (4, 48, 74). 
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The previously mentioned study of Siracuse et al. also showed that 16% of patients who 
develop vascular graft infection have renal insufficiency. From the epidemiological point of 
view, our study has similar epidemiology, with 23% of patients having renal insufficiency in 
the ISD group and 16% in the VAC group (90). 
Alcohol and nicotine abuse are very well-known risk factors for atherosclerotic changes in 
blood vessels and are indirect factors for vascular graft infection. In our study, 71% in the ISD 
group and 66% in the VAC group had documented nicotine abuse at the time of initial vascular 
graft surgery. The study by Siracuse et al. showed that 38% of patients had a history of nicotine 
use or active nicotine abuse (90). Another study done by Hallihan et al. showed 92 (54%) from 
170 patients who underwent lower extremity vascular graft surgery had a history of nicotine 
abuse (39). These 2 studies showed that nicotine abuse, as well as alcohol abuse, varies a lot in 
different studies. According to most of the studies, nicotine has a negative effect not only on 
the cardiovascular system, but also on the implanted vascular graft. This can be seen in the 
review study by Willigendael et al., where they analyzed 29 studies that included information 
about the effect of nicotine on vascular graft failure after operation. The study showed 
significant differences between smokers and non-smokers who underwent vascular graft 
surgery (107).  
As already mentioned, the same relationship is seen with alcohol consumption and graft 
infection. Alcohol in low dosages can actually reduce cardiovascular risk; however, if alcohol 
is used in higher dosages, it has a negative effect on the cardiovascular system, and in case of 
vascular graft surgery, on the vascular graft. Singh et al. did a retrospective study for an 8-year 
period, where they included 14788 patients who underwent lower extremity vascular graft 
surgery. The patient’s characteristics revealed that 11.6% of all patients had alcohol 
consumption in the history (87). In our study, 38% of all patients in the ISD group and 30% of 
all patients in the VAC group had alcohol consumption in their history. Another study done by 
Antonios et al. analyzed patients who underwent vascular graft surgery and had postoperative 
vascular graft failure. This study showed that alcohol consumption was seen in 11.9% of the 
vascular graft failure group and 6.9% in the control group (5).  The mentioned study confirms 
that alcohol use increases the risk of vascular graft infection development when compared with 
the control group. The differences seen with regard to alcohol consumption between studies 
can be explained by the fact that there is no definite criteria for alcohol consumption and 
different authors use different interpretations of the term. In general, alcohol consumption 
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refers to high dose of alcohol use daily; however, the amount of alcohol used varies between 
studies.    
Interestingly, cerebrovascular disease may be a risk factor for vascular graft infection 
development. Cerebrovascular diseases, such as ischemic strokes, are usually connected with 
development of atherosclerosis. The damaged vascular system due to atherosclerosis is a risk 
factor for PAD. In the results, if the cause for atherosclerosis, which includes the 
cerebrovascular system, are not reduced or liquidated, then the risk for vascular graft infection 
development becomes higher. The study by Hallihan et al. showed that cerebrovascular disease 
was diagnosed in 11% of patients who underwent lower extremity vascular graft surgery (39). 
In comparison with our study, cerebrovascular disease was documented for 7/21 (33%) patients 
in the ISD group versus 11/36 (30%) patients in the VAC group. 
ISD therapy as a successful vascular graft infection management method has already been 
described in 1980, when Popovsky et al. did an analysis of management methods for preserving 
infected grafts (77). ISD therapy was widely used in the past in cardiothoracic surgery for 
mediastinal infection and chronic sternal infection, but even in these studies, they failed to 
analyze the economic aspects of this treatment (72).   
ISD therapy can be used to manage not only chronic infections, but also acute surgical wound 
infections, as well. In cases of infected wounds, depending on the irrigation volume, it has also 
been associated with acceptable results (88). 
One of the explanations why ISD therapy as a management method is not analyzed from the 
economical aspect is because of its obviously low material costs, as there are no modern 
technologies involved.   
Thus, ISD can be used for small wounds that can be closed in a surgical manner. The material 
costs and personal costs for ISD therapy will be cheaper than those for VAC therapy, which 
uses commercially available and expensive VAC devices.  
Our study reports on the differences in the costs of negative wound pressure therapy, as well as 
in the outcomes of different devices used for surgical site infection treatment. In our 
department, we are using vacuum assisted devices (VAC®), which is one of most popular, and 
according to the study by Law et al., is cheaper compared to other negative wound pressure 
therapy devices (59).   
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We did calculations of graft infection management using the VAC or the ISD for a 1-week 
period and a 3-week period. Basically, the calculation analysis was done for a 1-week period, 
as the ISD therapy duration in our division is 1 week. VAC therapy can be done for a longer 
period of time, which will increase management costs. For this reason, we also did a 3-week 
cost analysis, to show the VAC treatment cost in this period. The 3-week period was used 
because our results showed that maximal VAC therapy duration was 24 days. In addition, 
subsequent VAC therapy management in our study patients was possible; however, we did not 
analyze these anymore.  
ISD therapy was used only once in vascular graft infection complex therapy management. If 
the therapy results were ineffective, we switched to other management methods, which 
included VAC therapy.  
Unfortunately, VAC therapy failure in vascular graft infection management has been reported. 
Svensson et al. in their study reported about 33 vascular graft infections that were managed 
with VAC therapy. Six infected wounds or 18% of the infected vascular grafts that were 
managed with VAC therapy were unsuccessful. Of those 6, 4 patients died at the end of therapy 
(94). Another study done by Berger et al. showed VAC therapy success rate to be 82% of 
managed cases, which is more or less similar to the results of Svensson et al. It must be 
mentioned that in the study of Berger et al., the study population showed 100% survival for a 
follow-up time of 380 days (10). 
Our study revealed that 3 patients in the ISD group and 3 patients in the VAC group 
encountered therapy failure. This resulted in an 8.3% treatment failure rate for the VAC group 
and a 14.2% failure rate in the ISD group. Our study showed better outcomes than those 
mentioned previously; we believe that there is a multifactorial influence that is important in 
VAC failure, specifically the combination of the bacteriological species causing infection, the 
stage of infection, antibiotic therapy, and other comorbidities.  
The treatment cost analysis plays a very important role especially in the last few decades, where 
medical treatment costs have risen tremendously. Because of its multidisciplinary approach, 
long hospital stay and operative management, the cost of vascular graft infection treatment are 
very high. At the same time, not many studies analyze the economical aspect of vascular graft 
infection management. Many studies generally state that graft infection management is very 
expensive, without including the specific treatment cost analysis (76, 89). 
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VAC therapy can be applied in chronic surgical wound infection treatment. There are many 
studies analyzing the economic aspects of VAC therapy in different surgical fields. For 
example, an interesting study published by Mokhtari et al. included 38 patients who underwent 
coronary artery bypass surgery and developed deep sternal infection after initial operation, 
which was managed with VAC therapy. The coronary artery bypass operation costs were 17574 
USD, and in the case of infection, the treatment costs rise to an average of 26 670 USD. In 
severe infection cases, these costs reached up to 60 546 USD. Those results showed how 
tremendously high the costs can be if surgical site infection develops postoperatively (66).  
VAC therapy is an expensive infected wound treatment method. However, in spite of its high 
costs, VAC therapy shows benefit in faster management of infected wounds, which results in 
lower treatment costs when compared with other infection management methods. This is shown 
in the study of Vuerstaek et. al, where they stated that VAC treatment reduced hospital costs 
because patients with infected wounds treated with VAC were discharged 29 days after 
admission, in comparison to 45 days in patients whose wound was managed in another way 
(104).   
Svensson et al. analyzed the VAC therapy costs in patients with lower extremity vascular graft 
infection. From the 33 patients who were included in the study and were managed with VAC 
therapy, the median VAC therapy treatment costs were 1 299 € (from 210 € up to 7 416 €), with 
overall median treatment costs of 26 022 €. The average duration of VAC treatment was 20 
days (from 3 up to 119 days).  
In our study, we analyzed the period of up to the 3 weeks; this means that in day 21, our 
treatment costs, depending on the surgical wound area, can reach 815 €. Minimal VAC therapy 
treatment costs 276 €, which is more or less equal to the results of the study of Svensson et al. 
Our study did not include costs that were linked to the patient’s stay in the ICU or vascular 
surgery ward, as well as revision operation costs, which are more or less equal for both groups. 
Overall, there are few information available about the economical aspect of ISD therapy. 
Although this therapy method is well-known historically, there are no publications that looked 
at the economical aspect of this therapy method until now. 
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Conclusions 
Lower extremity vascular graft infection is a rare but serious condition, which is associated 
with a long hospital stay, increased mortality, and has a negative effect on the patient’s life 
quality. Moreover, vascular graft infection management is linked to high treatment costs. 
Risk factors, which can increase the likelihood of vascular graft infection development, are 
multifactorial. Risk factors with a negative effect on the implanted vascular graft include 
nicotine and alcohol abuse, which are important factors for atherosclerotic changes in the 
vascular system. Other important factor include diabetes mellitus, which is not only associated 
with atherosclerotic changes, but is also linked to decreased immunity and surgical wound 
healing. The data confirms the same risk factors that have been analyzed in other studies of 
lower extremity vascular graft infections. 
Our data analysis showed that not only traditional well-known risk factors play roles in vascular 
graft infection development, but other factors, such as the presence of hip prosthesis, 
osteosynthesis with plate or screws, and malnutrition or electrolyte imbalance, may result in 
infection, as well. Future prospective studies with larger patient  and control groups need to be 
performed to confirm this.       
The treatment for vascular graft infection includes different options; in the last two decades, 
one promising treatment method has become popular: the VAC therapy. Another modified 
therapy option includes ISD therapy.  
Both therapy options have good results in lower extremity vascular graft infection treatment. 
The differences between therapy results have not been seen and in the most cases, both 
therapies show successful results, in combination with antibiotic therapy and, if necessary, 
surgical treatment.  
VAC therapy compared with ISD therapy showed no statistical difference in hospital stay.\. 
Nonsignificant difference between groups in the hospital days are linked to different maximal 
therapy time in the ISD and the VAC groups. 
The amputation rates between the groups showed that amputation rates are higher in the VAC 
group when compared with the ISD group but without any statistical significance. The same 
results are seen in the mortality rates, which were slightly higher in the VAC group. For this 
parameter, no statistical significance between the groups were seen, as well.  
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ISD therapy is more cost-effective in comparison to VAC therapy and showed major benefits 
in the economical aspect when both treatment costs were analyzed. Moreover, ISD therapy is 
simple to apply and requires minimal equipment to be performed when compare with VAC 
therapy, which requires more technological skills from the surgeon. 
The treatment period time is shorter in the ISD therapy group compare to the VAC therapy 
group. 
The negative aspect of ISD therapy is its limitation for vascular graft infections. Specifically, 
this type of therapy can be used only for relative small wounds where wound closure is possible. 
For vascular graft infections combined with surgical tissue infections that require wound tissue 
debridement resulting in large wound areas with no options to close the wound, ISD therapy 
cannot be performed. Other negative aspect include allergically reaction on iodine. In such case, 
the VAC therapy is superior to the ISD therapy, because of iodine containing disinfection liquid 
used in wound drainage.   
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Figures 
 
Figure 1 
 
Gender Characteristics of VAC vs. ISD Group 
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Figure 2 
Anatomical Location of Infection in VAC vs. ISD Group 
 
 
 
  
64 
 
Figure 3 
 
Previous Ipsilateral Vascular Bypass Graft Surgery in VAC vs ISD Group 
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Figure 4 
 
Foreign Material in the Ipsilateral Site  
of Vascular Graft in VAC vs. ISD Group 
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Figure 5 
 
Clinical Outcomes of VAC vs. ISD Group 
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Figure 6 
Diabetic Foot in VAC vs. ISD Group 
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Figure 7a 
 
Endocrine Disorders in VAC vs. ISD Group 
Hypolipoproteinemia  
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Figure 7b 
 
Endocrine Disorders in VAC vs. ISD Group 
Hypercholesterinemia  
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Figure 8 
 
VAC vs. ISD Therapy Costs, 7-day Period 
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Figure 9 
VAC vs. ISD Therapy Costs, 21-day Period 
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Tables 
Table 1 
 
Age in VAC Group vs. ISD Group 
 N Minimum Maximum Mean 
Std. 
Deviation 
Irrigation suction 
drainage 
Age, years 21 34 82 66.7 11.38 
      
Vacuum assisted 
closure therapy 
Age, years 36 55 90 71.3 9.91 
      
 
  
73 
 
 
 
Table 2 
 
Patient Characteristics 
 
Gender  
Number 
of 
patients Minimum Maximum Mean 
Std. 
Deviat
ion 
Female Irrigation suction 
drainage 
Height (cm) 7 164 172 166.00 3.21 
Weight  (kg) 7 68 120 86.29 16.99 
BMI (kg/m^2) 7 25.3 42.0 31.28 5.824 
      
Vacuum assisted 
closure therapy 
Height (cm) 13 154 174 161.62 6.39 
Weight  (kg) 13 55 98 71.92 14.81 
BMI (kg/m^2) 13 22.0 36.4 27.41 4.82 
      
Male Irrigation suction 
drainage 
Height (cm) 14 168 183 175.29 4.44 
Weight  (kg) 14 63 118 84.29 16.37 
BMI (kg/m^2) 14 21.0 37.2 27.38 4.91 
      
Vacuum assisted 
closure therapy 
Height (cm) 23 165 181 173.91 4.42 
Weight  (kg) 23 50 95 76.61 11.86 
BMI (kg/m^2) 23 18.4 30.4 25.27 3.46 
      
* BMI – body mass index 
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Table 3 
Szilagyi Classification in VAC vs. ISD Group 
 
 
  Patients Percent 
Irrigation suction drainage 
Grade 1 6 28.6 
2 8 38.1 
3 7 33.3 
Total number of 
patients 
21 100 
Vacuum assisted closure 
therapy 
Grade 1 8 22.2 
2 14 38.9 
3 14 38.9 
Total number of 
patients 
36  
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Table 4 
 
                                                Amputation Rates in VAC vs. ISD Group 
      Patients Percent 
Irrigation suction drainage   
Yes 7 33.3 
No 14 66.7 
Total number of 
patients 
21 100 
.Vacuum assisted closure 
therapy 
  
Yes 10 27.8 
No 26 72.2 
Total number of 
patients 
36  
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Table 5 
 
Hospital Stay (Days) in VAC vs. ISD Group 
  
Number of 
patients 
Minimum Maximum Mean 
Std. 
Deviation 
Irrigation suction 
drainage 
Hospital ward 
stay (Days) 
21 9 87 34.19 23.46 
ICU (Days) 21 0 19 4.86 6.382 
Vacuum assisted 
closure therapy 
Hospital ward 
stay (Days) 
36 10 126 37.72 26.263 
ICU (Days) 36 0 33 4.14 6.37 
 
* ICU – intensive care unit 
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Table 6 
 
                                               Average Therapy Days in VAC vs. ISD Group  
 
 
 
 
Number 
of patients 
Mean 
therapy 
days Std. Deviation 
Std. Error 
Mean 
 Irrigation suction drainage 21 7.23 0.43 0.09 
Vacuum assisted closure 
therapy 
36 14.88 5.53 0.92 
 
 
 
 
 
Independent Samples Test 
  t-test for Equality of Means 
  
F t df Sig. (2-tailed) Mean Difference 
Std. Error 
Difference   
Therapy days Equal variances assumed 33.055 -6.301 55 0.001 -7.65079 1.21415 
Equal variances not assumed  -8.252 35.743 0.001 -7.65079 0.92710 
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Table 7 
Bacteriological Characteristic in VAC vs. ISD Group 
  
Number of 
patients 
Percent 
Irrigation suction drainage   
Klebsiella 
Pneumoniae 
1 4.8 
Proteus Mirabilis 1 4.8 
Staphylococcus 
Lugdunensis 
2 9.5 
Pseudomonas 
Aeruginosa 
2 9.5 
Escherichia Coli 2 9.5 
Streptococcus 
Agalactiae 
2 9.5 
MRSA 3 14.3 
Enterococcus Faecalis 1 4.8 
Staphylococcus 
Aureus 
7 33.3 
Total Number of 
Patients 
21 100 
Vacuum assisted closure 
therapy 
  
Peptostreptococcus  
Species 
1 2.8 
Proteus Mirabilis 1 2.8 
Staphylococcus 
Lugdunensis 
1 2.8 
Pseudomonas 
Aeruginosa 
1 2.8 
Escherichia Coli 3 8.3 
MRSA 15 41.7 
Enterococcus Faecalis 3 8.3 
Staphylococcus 
Aureus 
9 25 
Staphylococcus 
Epidermidis 
1 2.8 
Clostridium Difficile 1 2.8 
Total Number of 
Patients 
36  
 
* MRSA – Methicillin-resistant Staphylococcus aureus 
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Table 8 
                                                                                
 
Antibiotic Therapy at least 24 hours before first vascular graft surgery in VAC vs. ISD 
Group 
 
 
 
 
 
 
 
 
 
 
Table 9 
 
Intraioperative Initial Antibiotic Therapy in VAC vs. ISD Group 
  
Number of 
patients 
Percent 
Irrigation suction drainage   
Cefuroxim 20 95.2 
Unacid 1 4.8 
Vacuum assisted closure 
therapy 
  
Cefuroxim 33 91.7 
Unacid 1 2.8 
Clindamycin 2 5.6 
 
 
  
  
Number of 
patients 
Percent 
Irrigation suction drainage   
Yes 3 14.3 
No 18 85.7 
Vacuum assisted closure 
therapy 
  
Yes 4 11.1 
No 32 88.9 
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Table 10 
Intraoperative Antibiotic Therapy at VAC or ISD Therapy Initiation 
 
    
Number of 
patients 
Percent 
Irrigation suction 
drainage 
Cefuroxim 10 47.6 
Vancomycin 5 23.8 
Linezolid 1 4.8 
Ciprofloxaci 3 14.3 
Cefadroxil 1 4.8 
Moxifloxacin 1 4.8 
Vacuum assisted 
closure therapy 
Cefuroxim 16 44.4 
Clindamycin 1 2.8 
Vancomycin 14 38.9 
Linezolid 2 5.6 
Cefazolin 1 2.8 
Piperacillin/Tazobactam 2 5.6 
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Table 11 
Blood Transfusion Units in VAC vs. ISD Group 
    
Number 
of 
Patients 
Minimu
m 
Maxim
um 
Mean 
Std. 
Deviation 
Irrigation 
suction 
drainage 
Amount of blood units 
transfusion in operation 
time  
21 0 4 0.76 1.17 
Amount of blood units 
transfusion in the first 
48 hours after revision 
surgery 
21 0 6 2.14 2.22 
Vacuum 
assisted 
closure 
therapy 
Amount of blood units 
transfusion in operation 
time  
36 0 2 0.58 0.90 
Amount of blood units 
transfusion in first 48 
hours after revision 
surgery 
36 0 6 1.67 1.69 
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Table 12 
Blood Transfusion Characteristics in VAC vs. ISD Group 
  Frequency Percent 
Irrigation suction 
drainage 
  
Yes 13 61.9 
No 8 38.1 
Total number 
of patients 
21 100 
Vacuum assisted closure 
therapy 
  
Yes 24 66.7 
No 12 33.3 
Total number 
of patients 
36  
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Table 13 
 
Vascular Graft Risk Factors Summary, VAC vs. ISD Group 
    
Irrigation suction 
drainage 
Percentage Vacuum 
assisted 
closure 
therapy 
Percent 
Insulin-dependent 
diabetes mellitus 
Yes 6 28.6 9 25 
No 15 71.4 27 75 
  
Non-insulin 
dependent diabetes 
mellitus 
Yes 3 14.3 5 13.9 
No 
18 85.7 31 86.1 
  
Renal insufficiency 
Yes 5 23.8 6 16.7 
No 16 76.2 30 83.3 
  
Dialysis Yes 3 14.3 2 5.6 
  No 18 85.7 34 94.4 
  
Liver failure 
Yes 2 9.5 1 2.8 
No 19 90.5 35 97.2 
  
Alcohol 
Yes 8 38.1 11 30.6 
No 13 61.9 25 69.4 
  
Smoking 
Yes 15 71.4 24 66.7 
No 6 28.6 12 33.3 
  
Respiratory disease 
No 11 52.4 19 52.8 
Chronic 
Bronchitis 
10 47.6 16 44.4 
Asthma 0 0 1 2.8 
  
Cerebrovascular 
disease 
Yes 7 33.3 11 30.6 
No 14 66.7 25 69.4 
  
Urinary tract 
infection 
Yes 2 9.5 1 2.8 
No 19 90.5 35 97.2 
            
Malnutrition 
Yes 1 4.8 4 11.1 
No 20 95.2 32 88.9 
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Chemotherapy 
Yes 0 0 1 2.8 
No 21 100 35 97.2 
  
Radiation therapy 
Yes 0 0 1 2.8 
No 21 100 35 97.2 
  
Immunosuppression 
Yes 0 0 2 5.6 
No 21 100 34 94.4 
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Table 14a 
First Revision Operation Time in VAC vs. ISD Group 
 
  
Number of 
patients 
Minimum Maximum Mean 
Std. 
Deviation 
Irrigation 
suction drainage 
Length of 
operation, min 
21 70 320      167 73.22 
Vacuum 
assisted closure 
therapy 
Length of 
operation, min 
36 56 280 156 56.29 
 
Table 14b 
Operation Time of VAC System Change 
  
Number 
of 
patients 
Minimum Maximum Mean 
Std. 
Deviation 
Vacuum 
assisted 
closure 
therapy 
Length of 
operation, min 
36 25 105 54.3333 17.35 
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Table 15 
Sodium Levels Before Initial Vascular Graft Surgery in VAC vs. ISD Group 
 
  
Number of 
patients 
Percent 
Irrigation suction drainage 
Normonatremia 15 71.4 
Hyponatremia 6 28.6 
Vacuum assisted closure 
therapy 
Normonatremia 27 75 
Hyponatremia 9 25 
 
 
Table 16 
Potassium Level Before Initial Vascular Graft Surgery in VAC vs. ISD Group 
 
  
Number of 
patients 
Percent 
Irrigation suction 
drainage 
Normokalemia 19 90.5 
Hyperkalemia 1 4.8 
Hypokalemia 1 4.8 
Vacuum assisted closure 
therapy 
Normokalemia 33 91.7 
Hyperkalemia 3 8.3 
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Table 17 
 
Leucocyte Levels (10^9/l) in VAC vs ISD Group 
 
 
 Minimum Maximum Mean 
Std. 
Deviation 
Irrigation suction 
drainage 
Leucocytes 
before initial 
operation 
3.97 31.35 10.98 6.19 
Leucocytes 
before VAC or 
ISD therapy 
begin 
10.75 34.98 19.14 5.96 
Leucocytes 
before discharge 
from clinic 
5.18 24.00 10.37 4.74 
     
Vacuum assisted 
closure therapy 
Leucocytes 
before initial 
operation 
4.00 16.40 9.41 2.80 
Leucocytes 
before VAC or 
ISD therapy 
begin 
7.24 30.47 17.01 4.54 
Leucocytes 
before discharge 
from clinic 
4.35 21.10 10.37 3.01 
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Table 18 
 
Haemoglobin Levels (g/dl) in VAC vs. ISD Group 
 
 
 
 Minimum Maximum Mean 
Std. 
Deviation 
Irrigation suction 
drainage 
Haemoglobin 
before initial 
operation 
8.8 16.7 12.81 2.23 
Haemoglobin 
before VAC or 
ISD therapy 
begin 
6.1 11.5 8.50 1.70 
Haemoglobin 
before discharge 
from clinic  
7.4 14.1 10.81 2.06 
     
Vacuum assisted 
closure therapy 
Haemoglobin 
before initial 
operation 
7.0 17.4 11.85 2.36 
Haemoglobin 
before VAC and 
ISD therapy 
begin 
6.5 12.5 8.45 1.48 
Haemoglobin 
before discharge 
from clinic 
8.0 13.7 10.58 1.42 
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Table 19 
 
C reactive protein levels (mg/dl) in VAC vs. ISD group 
 
 
 
 Minimum Maximum Mean 
Std. 
Deviation 
Irrigation suction 
drainage 
C Reactive 
Protein before 
initial operation 
0.1 33.6 6.80 11.27 
C Reactive 
Protein before 
VAC or ISD 
therapy begin 
9.4 44.9 21.77 9.64 
C Reactive 
Protein before 
discharge form 
clinic 
0.2 31.5 4.49 7.06 
     
Vacuum Assisted 
closure therapy 
C Reactive 
Protein before 
initial operation 
0.1 27.7 2.45 5.80 
C Reactive 
Protein before 
VAC or ISD 
therapy 
1.2 47.0 22.03 10.98 
C Reactive 
Protein before 
discharge form 
clinic 
0.1 21.4 3.74 4.86 
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Table 20 
Infection at the time of Initial Vascular Graft Surgery in VAC vs. ISD Group 
 
  
Number of 
patients 
Percent 
Irrigation suction drainage   
Yes 4 19 
No 17 81 
Vacuum assisted closure 
therapy 
  
Yes 4 11.1 
No 32 88.9 
 
 
 
Table 21 
ISD Therapy Costs 
 
ISD initial therapy material costs 
  € 
NaCl 0,9% 1000ml Ecotainer Spül 3570160 0.83 
Vicryl viol gefl 2-0 6x45 V1226H 3.44 
Vicryl viol gefl 2-0 6x45 V1226H 3.44 
Prolene blau 3-0 120 2XSH EH7584H 3.14 
Prolene blau 3-0 120 2XSH EH7584H 3.14 
Urindrainages. m. Hahn 2L steril 690212 1.49 
Urindrainages. m. Hahn 2L steril 690212 1.49 
Betaisodonna Lösung 120 ml 3.53 
Sum 20.50 
    
ISD therapy material daily costs 
NaCl 0,9% 1000ml Ecotainer Spül 3570160 0.83 
Betaisodonna Lösung 120 ml 3.53 
Sum 4.36 
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Table 22 
VAC Therapy Initial Costs According to Wound Area 
 
Initial VAC therapy material costs (small wound) 
Antimikrobielle Gaze-Rolle Kerlix 11,4cm 7.14 
Cutimed Sorbact  Wundf. 17x28cm 7269300 3.55 
PICO 10x20cm Einmalunterdr.-System/Verb. 165.41 
Renasys Gelstreifen 10x7cm 66801082 4.76 
Renasys GO 300 ml Kanister 66800914 23.21 
Renasys GO Tragegurt 66800163 20.23 
Renasys Port-Kit 66800799 20.47 
Renasys Y-Konnektor  66800971 5.53 
Schaumst.-Kit, klein 10x8 x3cm 66800794 25.79 
Transp. NPWT Folie,groß  20x30  66800394 6.08 
Sum 276.08 
 
Initial VAC therapy material costs (medium wound) 
Ant+A22:B47imikrobielle Gaze-Rolle Kerlix 11,4cm 7.14 
Cutimed Sorbact  Wundf. 17x28cm 7269300 3.55 
PICO 10x30cm Einmalunterdr.-System/Verb. 165.41 
Renasys Gelstreifen 10x7cm 66801082 4.76 
Renasys GO 300 ml Kanister 66800914 23.21 
Renasys GO Tragegurt 66800163 20.23 
Renasys Port-Kit 66800799 20.47 
Renasys Y-Konnektor  66800971 5.53 
Schaumst.-Kit,mittel 20x12,5x3 66800795 31.54 
Transp. NPWT Folie,groß  20x30  66800394 6.08 
Sum 287.91 
 
Initial VAC therapy material costs (large wound) 
Antimikrobielle Gaze-Rolle Kerlix 11,4cm 7.14 
Cutimed Sorbact  Wundf. 17x28cm 7269300 3.55 
PICO 10x40cm Einmalunterdr.-System/Verb. 165.41 
Renasys Gelstreifen 10x7cm 66801082 4.76 
Renasys GO 300 ml Kanister 66800914 23.21 
Renasys GO Tragegurt 66800163 20.23 
Renasys Port-Kit 66800799 20.47 
Renasys Y-Konnektor  66800971 5.53 
Schaumst.-Kit, groß  25x15  x3  66800796 37.07 
Transp. NPWT Folie,groß  20x30  66800394 6.08 
Sum 293.44 
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Table 23 
                      
                          VAC Change Costs According to Wound Area 
 
VAC change therapy material costs (small wound) 
Antimikrobielle Gaze-Rolle Kerlix 11,4cm 7.14 
Cutimed Sorbact  Wundf. 17x28cm 7269300 3.55 
Renasys Gelstreifen 10x7cm 66801082 4.76 
Renasys Port-Kit 66800799 20.47 
Renasys Y-Konnektor  66800971 5.53 
Schaumst.-Kit, klein 10x8 x3cm 66800794 25.79 
Transp. NPWT Folie,groß  20x30  66800394 6.08 
Sum 73.32 
 
VAC change therapy material costs (medium wound) 
Antimikrobielle Gaze-Rolle Kerlix 11,4cm 7.14 
Cutimed Sorbact  Wundf. 17x28cm 7269300 3.55 
Renasys Gelstreifen 10x7cm 66801082 4.76 
Renasys Port-Kit 66800799 20.47 
Renasys Y-Konnektor  66800971 5.53 
Schaumst.-Kit,mittel 20x12,5x3 66800795 31.54 
Transp. NPWT Folie,groß  20x30  66800394 6.08 
Sum 79.06 
 
VAC change therapy material costs (large wound) 
Antimikrobielle Gaze-Rolle Kerlix 11,4cm 7.14 
Cutimed Sorbact  Wundf. 17x28cm 7269300 3.55 
Renasys Gelstreifen 10x7cm 66801082 4.76 
Renasys Port-Kit 66800799 20.47 
Renasys Y-Konnektor  66800971 5.53 
Schaumst.-Kit, groß  25x15  x3  66800796 37.07 
Transp. NPWT Folie,groß  20x30  66800394 6.08 
Sum 84.60 
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Table 24 
                                  VAC Therapy Costs by End of VAC Therapy 
 
Vacuum assisted closure (Wound Closure end therapy) 
NaCl 0,9% 1000ml Ecotainer Spül 3570160 0.83 
Vicryl viol gefl 2-0 6x45 V1226H 3.44 
Vicryl viol gefl 2-0 6x45 V1226H 3.44 
Prolene blau 3-0 120 2XSH EH7584H 3.14 
Prolene blau 3-0 120 2XSH EH7584H 3.14 
Sum 13.99 
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Table 25 
VAC vs. ISD Therapy Costs, 7-day Period 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Irrigation suction drainage 20.5 24.86 29.22 33.58 37.94 38.83 38.83 
Vacuum assisted closure therapy (Small wound) 276.08 276.08 276.08 349.4 349.4 349.4 363.39 
Vacuum assisted closure therapy (Medium wound) 287.91 287.91 287.91 366.97 366.97 366.97 380.96 
Vacuum assisted closure therapy (Large wound) 293.44 293.44 293.44 378.04 378.04 378.04 392.03 
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Table 26 
VAC vs. ISD Therapy Costs, 21-day Period 
 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Irrigation suction Drainage 20.5 24.86 29.22 33.58 37.94 38.83 38.83 
Vacuum assisted closure Therapy (Small wound) 276.08 276.08 276.08 349.4 349.4 349.4 422.72 
Vacuum assisted closure Therapy (Medium 
wound) 
287.91 287.91 287.91 366.97 366.97 366.97 446.03 
Vacuum assisted closure Therapy (Large wound) 293.44 293.44 293.44 378.04 378.04 378.04 462.64 
               
 Day 8 Day 9 Day 10 Day 11 Day 12 Day 13 Day 14 
Irrigation suction drainage               
Vacuum assisted closure therapy (Small wound) 422.72 422.72 496.04 496.04 496.04 569.36 569.36 
Vacuum assisted closure therapy (Medium 
wound) 
446.03 446.03 529.09 529.09 529.09 604.15 604.15 
Vacuum assisted closure therapy (Large wound) 462.64 462.64 547.24 547.24 547.24 631.84 631.84 
               
 Day 15 Day 16 Day 17 Day 18 Day 19 Day 20 Day 21 
Irrigation suction drainage               
Vacuum assisted closure therapy (Small wound) 569.36 642.68 642.68 642.68 716 716 729.99 
Vacuum assisted closure therapy (Medium 
wound) 
604.15 683.21 683.21 683.21 762.27 762.27 776.26 
Vacuum assisted closure therapy (Large wound) 631.84 716.44 716.44 716.44 801.04 801.04 815.03 
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